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In	 1951	 the	 human	 cell	 line	HeLa	was	 derived	 from	 cervical	 cancer	 cells	 from	
patient	Henrietta	Lacks	(Gey	et	al.,	1952).	This	cell	line	is	naturally	“immortal”	due	
to	 expression	 of	 telomerase	 during	 cell	 division	which	 prevents	 shortening	 of	
telomeres	 and	 therefore	 cellular	 senescence,	 and	 even	 for	 a	 cancer	 cell,	 grows	
unusually	 fast	 (Ivankovic	 et	 al.,	 2007).	 This	 made	 it	 the	 perfect	 candidate	 for	
medical	and	biological	research,	as	it	had	until	then	been	difficult	to	culture	and	
sustain	 stocks	of	 living	cells	 for	 research.	Although	a	 cancer	cell	 line,	HeLa	has	










and	 ability	 to	 clone	 and	 mass	 produce	 the	 cell	 line	 with	 relative	 ease	 at	 low	
expense	led	to	ground	breaking	scientific	discovery.	
	
The	greatest	 implication	of	 the	HeLa	cancer	cell	 line	was	not	only	the	potential	
new	 understanding	 of	 cancer,	 but	 the	 ability	 to	 now	 study	 many	 biological	
processes,	 diseases	 and	 drug	mechanisms	 using	 human	 cells	 in	 vitro.	 Diseases	
including	diphtheria	(Strauss	and	Hendee,	1959)	and	adenoviruses	(Boyer	et	al.,	
1957)	were	 researched	using	HeLa	 cells	 early	on,	 and	HeLa	 cells	were	used	 to	










were	 previously	 difficult	 to	 do	 so	 including	 cancer	 initiation,	 progression	 and	
metastasis.	 However,	 as	 these	 new	 cell	 lines	 have	 been	 established	 over	 time,	































origin,	 highlighting	 inter-	 and	 intraspecies	 contamination	 of	 cell	 cultures.	 This	
revelation,	 and	Nelson-Rees,	was	 perhaps	 unsurprisingly	 not	 popular	 amongst	
some	scientists,	and	work	continued	to	be	published	containing	false	information	
(Nelson-Rees,	2001).	This	eventually	led	to	Nelson-Rees	losing	his	position	at	the	

















and	 colleagues.	 They	 had	 determined	 that	 the	 number	 of	 passages	 a	 cell	 line	
underwent,	 that	 is	 the	 number	 of	 times	 the	 cell	 culture	 had	 been	 subcultured,	
could	lead	to	vast	changes	in	characteristics	that	meant	it	no	longer	represented	




high	 passage	 number	 by	 using	 cell	 lines	 from	 trusted	 sources,	 carrying	 out	





of	 misidentification	 and	 misclassification	 of	 cancer	 cell	 lines	 was	 further	
highlighted	nearly	 two	decades	 later.	Advances	 in	 techniques	used	 to	highlight	












name	was	 therefore	 changed	 to	NCI/ADR-RES.	 Further	 analysis	 of	 the	 cell	 line	
through	comparison	with	the	other	59	cell	lines	in	the	panel	(Roschke	et	al.,	2003)	








So	 even	 though	 concerns	 of	 cancer	 cell	 line	 misidentification	 and	 cross-
contamination	 brought	 to	 light	 by	Gartler	 and	Nelson-Rees	were	 not	met	with	
resistance	by	all,	and	quality	control	steps	were	implemented	and	adhered	to,	the	
number	of	cell	 lines	misidentified	or	misclassified	had	not	been	reduced	by	the	
start	 of	 the	 21st	 century,	 but	 actually	 increased.	 The	 American	 type	 culture	





cell	 lines)	 and	 secondary	 sources	 (Drexler	 et	 al.,	 2003).	 This	 finding	 was	
particularly	 interesting	 as	 there	 was	 no	 significant	 difference	 between	 the	
incidence	of	misidentified	cell	lines	from	primary	sources	(14.9%)	and	secondary	
sources	 (14.8%),	 that	 there	 was	 as	 much	 chance	 that	 cross	 contaminations	
occurred	 during	 attempted	 establishment	 of	 a	 new	 cell	 line	 as	 all	 being	 cross-
contaminated	by	secondary	investigators.	A	year	later	a	survey	was	carried	out,	
and	out	of	483	replies	to	the	survey	for	active	cell	culture	workers	“32%	used	HeLa	
cells,	 9%	 were	 unwittingly	 using	 HeLa	 contaminants,	 only	 33%	 of	 the	
investigators	tested	their	cell	 lines	 for	authenticity	and	35%	obtained	their	cell	
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misidentification	 revolution	 led	by	Roland	Nardone.	With	 the	 support	 of	many	
scientists,	 organisations	 such	 as	 the	 NIH	 and	 the	 Howard	 Hughes	 Medical	















meaning	 that	 with	 less	 complacency	 in	 laboratories,	 and	 regular	 cell	 line	
authentication,	misidentification	numbers	could	be	drastically	reduced.	They	also	











Misidentification	 and	 cross-contamination	 are	 not	 the	 only	 factor	 to	 consider	
when	 regarding	 cell	 line	 suitability	 in	 research.	 Tumours	 are	 extremely	
heterogeneous.	This	means	 that	 in	 a	 given	 tumour,	we	 see	 cell	 subpopulations	
with	 distinct	 geno-	 and	 phenotypes	 that	 may	 display	 different	 biological	








cell	 lines	 is	 that	 research	 can	be	 carried	out	 on	 them	 that	would	otherwise	be	









Figure	 1.1	 Cancer	 Clonal	 Theory.	 Genetic	 instability	 of	 cancer	 cells	 leads	 to	 production	 of	
variants	and	those	with	mutations	that	promote	additional	selective	advantage	thrive	and	create	
subpopulations	 within	 the	 tumour.	 Different	 environmental	 pressures	 are	 responsible	 for	






2006).	 Hierarchical	 cluster	 analysis	 was	 carried	 out	 with	 cell	 line	 and	 gene	
expression	patterns	compared	between	cell	 lines	and	primary	 tumour,	and	 the	
same	 method	 was	 used	 for	 genome	 aberrations.	 The	 frequency	 of	 significant	
increases	or	decreases	in	genome	copy	number	were	also	compared	between	cell	
line	 and	 primary	 tumour.	 They	 concluded	 that	 the	 panel	 of	 51	 cell	 lines	 as	 a	
system,	 not	 individually,	mirrors	 the	 genomic	 heterogeneity	 and	 the	 recurrent	
genome	copy	number	abnormalities	found	in	primary	tumours,	but	that	they	also	











that	 presence	 of	 nonparenchymal	 cells	 (that	 is	 cells	 that	 are	 not	 colorectal	 in	
origin)	in	primary	tumour	and	gene	expression	alterations	caused	when	creating	
the	in	vitro	cell	cultures	were	the	reason	for	the	differences	observed	between	cell	
















Gillet	 et	 al.	 (2012)	 iterate	 that	 genomic	 and	 transcriptomic	 changes	 should	 be	
clearly	distinguished	when	comparing	cell	line	and	primary	tumour	as	it	has	been	
repeatedly	shown	that	driver	mutations	are	almost	always	retained.	This	has	been	
previously	 discussed	 (Neve	 et	 al.,	 2006).	 Gillet	 et	 al.	 proceeded	 to	 compare	
expression	profiles,	for	a	selection	of	genes,	of	112	ovarian	tumour	samples	(80	
untreated,	 32	 unpaired	 samples	 obtained	 at	 diagnosis	 or	 at	 recurrence	 after	
chemotherapy)	with	a	panel	of	ovarian	cancer	cell	 lines	either	grown	 in	 three-
dimensional	culture	or	as	xenografts,	or	from	the	NCI-60	panel.	They	discovered	
that	 cell	 lines,	 grown	 in	 vitro	 or	 in	 vivo,	 and	 clinical	 samples	 clustered	 in	 two	
distinct	groups.	Addition	of	the	remainder	of	the	NCI-60	cell	lines	(from	8	other	
tissues	 of	 origin)	 into	 this	 analysis,	 clustering	was	 also	 in	 two	 groups:	 clinical	
samples	and	cell	lines.	The	cell	lines,	regardless	of	their	tissue	of	origin,	were	bore	
more	 resemblance	 to	 each	 other	 than	 the	 primary	 tumour	 samples	 they	were	
supposed	 to	 model.	 Using	 90	 cell	 lines	 of	 six	 different	 tissue	 types	 they	 also	
determined,	using	fold	change	of	gene	expression	for	each	tissue	type	(cell	 line	
and	primary	 tumour),	 that	 cell	 lines	and	primary	 tumour	of	 the	 same	 type	are	
more	similar	 to	each	other	 than	cell	 line/primary	 tumours	pairs	 from	different	
tissues.	So	overall	it	was	found	that	although	cell	lines	have	very	different	genomic	




















The	 consensus	 of	 research	 on	 how	 the	 characteristics,	 and	 therefore	
heterogeneity,	 of	 the	primary	 tumour	 is	 represented	 is	 that	 there	 are	 genomic	









1. It	 could	 enable	 the	 study	 of	 cooperative	 and	 competitive	 interactions	
between	 cell	 populations	 –	 that	 is	 it	 could	 help	 us	 understand	 which	
mutations	may	drive	drug	 resistance	or	 contribute	 to	 cancer	population	
survival	after	treatment.	
2. Comparisons	 between	 genetics	 between	 original	 cells	 and	 cells	 that	 are	
genetic	 variants	 (but	 originate	 from	 those	 cells)	 may	 give	 insight	 into	















traits	of	 the	primary	 tumour.	They	also	 inherit	 “immortality”	 from	 their	
parent	cells	most	often	due	to	their	expression	of	telomerase	(Counter	et	
al.,	1992;	Chiu	and	Harley,	1997),	so	unlike	normal	cells	there	is	no	limit	to	








Cancer	 cell	 lines,	 if	 not	 established	 from	 primary	 tumour	 in	 lab,	 would	
come	at	one	initial	cost.	As	cell	lines	can	be	frozen,	defrosted,	grown	and	
frozen	 again,	 it	 is	 not	necessary	 to	purchase.	But	perhaps	 “inexpensive”	
should	be	thought	of	in	terms	of	time,	that	is	time	to	grow	and	maintain	the	






Due	 to	 the	 2D	 nature	 of	 cancer	 cell	 line	 culture,	 that	 is	 they	 grow	 as	
monolayers,	makes	them	perfect	for	use	in	high-throughput	screening	of	






high	variety	of	 cancer	 cell	 lines	available,	means	 that	 researchers	already	have	
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access	to	many	different	possible	cancer	models.	Many	types	of	cancer	and	tissue	
type	are	available,	 for	example	over	1000	cancer	 cell	 lines	 from	16	 tissues	are	
available	from	the	ATCC.	Another	advantage	is	their	genomic	similarity	with	their	
primary	tumour.	As	stated	earlier,	although	cancer	cell	lines	don’t	mirror	primary	
tumour	heterogeneity	or	gene	expression	profile	 to	any	great	extent,	 there	 is	a	



















was	 the	 American	 Type	 Culture	 Collection	 (ATCC),	 an	 organisation	which	was	
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established	 to	 collect,	 authenticate,	 store	 and	 distribute	 reference	
microorganisms,	 and	 in	 1962	 they	 began	 to	 do	 the	 same	with	 cell	 lines.	Other	
cancer	cell	line	panels	would	not	only	store	cell	lines	however,	and	in	the	1980s	
as	the	demand	for	identification	of	novel	anticancer	compounds	increased,	a	panel	







cell	 lines	 that	 represented	 the	 prevalence	 of	 stomach	 cancer	 in	 the	 Japanese	
population.	Since	the	conception	of	these	two	panels,	many	more	have	spawned	
with	 different	 goals,	 for	 individual	 tumour	 types	 or	 for	 testing	 of	 certain	 drug	
types,	or	for	investigation	of	mechanisms	of	drug	resistance.	The	LL-100	is	a	cell	
line	panel	that	collects	100	cell	lines	covering	22	entities	of	human	leukaemia	and	
lymphoma	 (Quentmeier	 et	 al.,	 2019).	 They	 believed	 that	 all	 leukaemia	 and	
lymphoma	 cell	 lines	were	 not	 represented	 by	 previous	 cell	 line	 panels	 and	 so	
developed	 this	 specialised	 cell	 panel.	 The	 Resistant	 cancer	 cell	 line	 collection	


















Malignancy	 CCLE	 GDSC	 CTRP	 NCI-60	 Unique	
Bladder	 28	 18	 5	 0	 29	
Bone	 29	 31	 1	 0	 53	
Breast	 60	 43	 1	 5	 64	
Cervix	 0	 12	 0	 0	 12	
Colon	 63	 35	 37	 7	 70	
Endometrium	 28	 10	 11	 0	 29	
Head	and	neck	 35	 23	 2	 0	 44	
Hematopoietic	and	
lymphoid	 181	 113	 24	 6	 227	
Kidney	 36	 22	 2	 8	 48	
Liver	 36	 14	 4	 0	 41	
Lung	 187	 141	 91	 9	 226	
Nervous	system	 86	 79	 3	 6	 126	
Osephagus	 27	 23	 3	 0	 29	
Ovary	 52	 20	 26	 7	 57	
Pancreas	 46	 17	 10	 0	 47	
Prostate	 8	 5	 1	 2	 9	
Skin	 62	 45	 9	 10	 79	
Soft	tissue	 21	 17	 3	 0	 28	
Stomach	 38	 18	 6	 0	 44	
Testis	 0	 2	 0	 0	 2	
Thyroid	 12	 12	 0	 0	 16	
Other	 11	 7	 3	 0	 20	
Total	#	of	cell	lines	 1,046	 707	 242	 60	 1300	
Total	#	of	agents	









response	 to	 the	 limited	 success	 of	 identifying	 new	 anticancer	 compounds	 for	
human	solid	tumours	using	transplanted	murine	neoplasm	models	(Boyd,	1997).	
A	total	of	60	cell	 lines	 from	nine	different	cancer	types	were	established	 in	the	
panel,	a	feat	that	was	not	easy	at	the	time	due	to	the	concerns	over	cell	line	cross-
contamination	 and	misidentification	 that	 had	been	brought	 to	 light	 less	 than	 a	
decade	earlier.	Painstaking	work	was	carried	out	to	obtain	low	passage	cell	lines	
that	 represented	 the	 nine	 cancer	 types,	 ensuring	 patterns	 of	 expression	 were	
consistent	with	their	primary	tumours	(Stinson	et	al.,	1992).	Although	it	is	now	
















TGI	 to	 essentially	 compare	 the	Mean	Graph	patterns.	 Initial	NCI	 findings	using	
COMPARE	observed	that	compounds	that	had	similar	Mean	Graphs	were	often	of	
similar	 structure,	 and	 further	more	whether	 similar	 in	 structure	or	not,	would	
share	 the	 same	 or	 related	 mechanism	 of	 action	 (Paull	 et	 al.,	 1995).	 This	 is	
highlighted	 in	 figure	1.2,	 the	Mean	Graphs	are	very	similar	 for	 carboplatin	and	
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Through	 this	 early	 work	 carried	 out	 by	 the	 NCI-60,	 many	 compounds	 were	
identified	for	in	vivo	testing	and	as	a	result	the	NCI	developed	novel	ways	to	speed	
up	the	process	by	bypassing	traditional	human	tumour	xenografts	(Hollingshead	
et	 al.,	 1995),	 and	 when	 prescreening	 and	 high-throughput	 methods	 were	
implemented,	the	entire	drug	screening	and	testing	process	was	a	formidable	tool	
in	the	battle	against	cancer.	This	has	suited	their	method	of	the	screening	of	many	
compounds	 on	 a	 relatively	 small	 number	 of	 cancer	 cell	 lines.	 Incidently,	 even	
reduced	 numbers	 of	 cell	 lines	 compared	 to	 the	 60	 in	 this	 panel	 support	 the	










Proscript	 Pharmaceuticals	 submitted	 the	 compound	 bortezomib	 for	 screening	
and	COMPARE	analysis	and	the	result	was	COMPARE-negative.	This	meant	that	
the	 bortezomib	Mean	 Graph	 did	 not	 compare	 with	 any	 other	 compounds	 and	
indicated	an	unknown	mechanism	of	action,	one	 that	was	distinct	 from	known	
anticancer	drugs.	This	warranted	further	investigation	and	after	eventual	clinical	





NCI-60	were	 reduced	and	 compared	 to	when	 the	 screen	was	 implemented	 the	











2012).	They	undertook	a	different	 approach	 to	 the	NCI-60.	Rather	 than	 screen	
many	 compounds	 against	 few	 cell	 lines,	 they	 screened	 few	 compounds	 against	
many	 cell	 lines.	 This	 would	 give	 them	 best	 chance	 of	 achieving	 their	 goal,	 to	
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identify	 genomic	 predictors	 of	 drug	 response.	 The	 cell	 line	 panel	 consisted	 of	
~1000	cancer	 cell	 lines,	however	 ,	 the	drug	screening	was	carried	out	with	24	
compounds	 across	 only	 504	 of	 the	 cell	 lines,	 representing	 21	 different	 cancer	
types.	A	large-scale	genomic	dataset	was	generated	using	947	of	the	cell	lines,	the	
data	 included	mutational	 status	 of	 1651	 genes,	 DNA	 copy	 number,	 and	mRNA	
expression	levels.	Measurements	of	cell	line	sensitivity	were	determined	using	8-
point	dose	response	curves,	resulting	in	values	for	maximal	effect	level	(Amax),	the	
concentration	 at	 half-maximal	 activity	 of	 the	 compound	 (EC50)	 and	 the	
concentration	at	which	the	drug	response	reached	50%	inhibition	(IC50).	If	the	
IC50	was	not	reached	for	a	cell	line,	the	maximum	concentration	of	8uM	was	given	














methods	 they	 identified	 unknown	 relationships	 including	 topoisomerase	 I	
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inhibitor	 irinotecan	 sensitivity	 and	 SLFN11	 expression,	 PD0325901	 and	 AHR	










line	 panel	 with	 as	 many	 cell	 lines	 from	 as	 many	 tumour	 types	 with	 genomic	
analysis	already	carried	out	on	them	is	obviously	a	great	resource	for	scientific	
researchers.	 Domke	 et	 al.	 (2013)	 evaluated	 the	 ovarian	 cancer	 cell	 lines	 to	
determine	whether	they	could	be	used	as	tumour	models.	Using	the	genomic	data	












new	 characteristics	 for	 the	 cancer	 cell	 lines	 in	 their	 panel.	Data	 available	 from	











The	 Genomics	 of	 Drug	 Sensitivity	 in	 Cancer	 (GDSC)	 project	 is	 a	 collaboration	
between	the	Cancer	Genome	Project	(CGP)	at	the	Wellcome	Sanger	Institute	and	
the	 Center	 for	Molecular	 Therapeutics,	Massachusetts	 General	 Hospital	 Cancer	
Center	 (Garnett	 et	 al.,	 2012;	 Yang	 et	 al.,	 2013).	 This	 study	 has	 received	many	
comparisons	with	 the	 CCLE	 as	 both	 are	 large-scale	 pharmacogenomics	 studies	
and	both	were	published	in	the	same	year.	As	with	the	CCLE,	the	GDSC	collects	a	




two	 studies.	 Expression	profiling	 of	 14,500	 genes	was	 carried	 out	 in	 the	GDSC	
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study,	 compared	 to	 just	 the	 1651	 for	 the	 original	 CCLE	 study	 (Barretina	et	 al.,	
2012).	
	
Measurement	 of	 compound	 activity	 for	 cell	 lines	 in	 this	 study	 varied	 from	 the	
previous	studies	discussed.	IC50	values	were	calculated	using	similar	methods	but	
calculations	 for	 cell	 lines	 that	 didn’t	 reach	 an	 IC50	 for	 a	 compound	 was	 not	
“capped”	at	the	highest	compound	dose	concentration	as	in	the	CCLE	and	NCI-60.	
An	algorithm	was	used	to	extrapolate	IC50	values,	resulting	in	IC50s	sometimes	




Using	 multivariate	 analyses	 of	 variance	 (MANOVA)	 and	 elastic	 net	 regression	













A	 highly	 significant	 association	 was	 identified	 between	 the	 EWS-FLI1	
rearrangement	 indicative	 of	 Ewing’s	 sarcoma	 tumours	 and	 PARP	 inhibitor	































(35	 FDA-approved	 drugs,	 54	 clinical	 candidates,	 265	 probes)	 and	 unlike	 the	
previous	 studies	 discussed,	 they	 chose	 the	 area	 under	 percent-viabilty	 curves	
(AUC)	 rather	 than	 IC50	 as	 there	 measure	 of	 drug	 sensitivity.	 They	 stated	 the	
reason	 for	 this	 was	 that	 they	 believed	 the	 AUC	 measurement	 reflected	 both	
relative	potency	and	total	level	of	inhibition	observed	for	a	compound.	Cell	lines	






drug	 associations	 were	 identified	 in	 the	 data.	 P-0850,	 a	 compound	 that	 is	 an	
analog	to	BRAF-V600E	inhibitor	vemurafenib	was	associated	with	sensitivity	to	
BRAF	mutated	cell	lines	and	that	EGFR-Mutant	lung	cancer	cell	lines	were	highly	
sensitive	 to	 HER2/EGFR	 inhibitor	 neratinib.	 New	 found	 associations	 included	














BMS-754807	 in	 neuroblastoma	 cell	 line	 NB1	 but	 not	 in	KRAS-mutant	 cell	 line	
LS513	showing	 that	 combination	 therapies	are	also	 targeted	as	 targeted	 single	
therapies	are.	Much	of	the	work	from	this	study	was	establishing	the	data	for	the	
CTRP	 version	 2	 (V2).	 Rees	 et	 al.	 (2016)	 used	 this	 data	 to	 correlate	 the	 small	
molecule	data	with	gene	expression.	One	of	the	standout	results	from	this	study	
was	 the	 correlation	 of	 SLC35F2	 and	 ABCB1	 expression	 with	 cell	 line	 YM-155	















pharmacogenomics	 studies.	 Benjamin	 Haibe-Kains	was	 at	 the	 forefront	 of	 this	
comparison.	 Haibe-Kains	 et	 al.,	 (2013)	 measured	 the	 correlation	 between	 the	
CCLE	and	GDSC	analyses.	15	drugs	and	471	cancer	cell	lines,	with	mutation	data	











than	 fair.	 Repeating	 the	 correlation	 but	 using	 AUC	 faired	 little	 better,	 median	
spearman	correlation	for	the	15	shared	rugs	0.28	when	using	IC50	as	sensitivity	
measurement	and	0.35	when	using	AUC.	Using	 linear	regression	models	on	the	
overlapping	 data	 to	 estimate	 gene-drug	 associations,	 results	 between	 the	 two	
studies	were	compared.	Again	highest	correlations	were	poor,	below	0.5,	using	
IC50	 or	 AUC	 as	 measure	 of	 drug	 sensitivity.	 Even	 using	 another	
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pharmacogenomics	 study	as	 another	 comparison,	 the	GlaxoSmithKline	 cell	 line	
collection	(GSK)	(Greshock	et	al.,	2010),	poor	correlation	was	observed	between	








authors	 of	 the	 original	 papers	 (Cancer	 Cell	 Line	 Encyclopedia	 Consortium	 and	
Genomics	 of	 Drug	 Sensitivity	 in	 Cancer	 Consortium,	 2015).	 They	 began	 by	
repeating	 correlation	 analysis	 on	 overlapping	 drugs	 (15)	 and	 cell	 lines	 (471).	
Importantly	though,	they	did	not	remove	data	that	was	extrapolated	in	the	GDSC	
data,	 but	 instead	 capped	 the	 cell	 line	 IC50	 at	 the	 maximum	 tested	 drug	
concentration.	Correlation	was	better	than	reported	by	Haibe-Kains	et	al.	and	the	
authors	 defend	 the	 correlation	 between	 data	 by	 explaining	 that	 in	 these	 large	
pharmacogenomics	 data	 sets,	 there	 will	 exist	 a	 drug-insensitive	 cell	 line	
dominated	 distribution.	 Most	 of	 the	 compounds	 target	 specific	 oncogenic	
dependencies	so	it	is	perhaps	unsurprising	that	there	are	relatively	few	“sensitive”	











on	 the	 shared	 data	 and	 observed	 known	 biomarkers	 that	 correlated	 in	 both	
studies	(NRAS	mutation	biomarker	for	MEK	inhibitor	PD0325901	sensitivity	and	
BRAF	mutations	to	BRAF	inhibitor	PLX4720	sensitivity	to	name	a	few).	Overall	the	
authors	 determined	 that	 the	 two	 screens	 exhibit	 broad	 convergence	 and	 also	

















had	both	 added	data	 to	 their	 respective	datasets.	 Safikhani	et	 al.	 also	question	
what	 constitutes	 agreement,	 and	 suggest	 that	 perhaps	 some	 of	 the	 correlation	
coefficients	that	were	said	to	be	good,	were	not.	They	come	to	the	same	conclusion	
as	in	their	first	paper	questioning	the	agreement	between	the	CCLE	and	GDSC,	that	






that	 the	 CCLE	 and	 GDSC	 strive	 to	 defend	 their	 work	 as	 does	 Haibe-Kains,	 so	
perhaps	the	study	by	Haverty	et	al.	(2016)	should	be	the	leading	authority	on	this	
subject.	The	general	consensus	though,	amongst	all	the	drama,	is	that	these	large-









aforementioned	 pharmacogenomic	 cell	 line	 studies.	 Despite	 potential	 negative	
side	 effects	 of	 these	 chemotherapeutic	 agents	 (Ruggiero	 et	 al.,	 2013),	


























Platinum	 compound	 have	 become	 a	 vital	 weapon	 in	 the	 fight	 against	 cancer.	
Cisplatin	was	the	first	to	be	approved	by	the	FDA	in	1978	just	nine	years	after	its	
discovery.	It	has	been	used	over	the	years	to	treat	many	cancer	types	and	is	often	
used	 in	 combination	with	 other	 drugs.	 The	 target	 for	 cisplatin	 is	 nuclear	DNA,	
guanine	bases	to	be	precise.	It	binds	to	both	strands	forming	a	crosslinking	of	the	
DNA,	which	attracts	DNA	repair	machinery	that	binds	irreversibly	to	the	complex,	
thus	 preventing	 actual	 repair	 and	 replication	 (Gomez-Ruiz,2012).	 Despite	 the	



















nephrotoxicity,	makes	 it	 a	 better	 candidate	 for	 treatment	 for	 patients	who	 are	
unable	to	tolerate	cisplatin	because	of	renal	impairment,	hearing	impairment	or	
neuropathy.	Side	effects	do	include	low	blood	count	which	can	lead	to	infection	by	
opportunistic	 organisms	 (Shaw	 et	 al.,	 1996).	 Mechanisms	 of	 resistance	 are	






predominantly	 nephrotoxic	 like	 cisplatin	 or	myelosuppressive	 like	 carboplatin,	
but	 rather	 neurotoxicity,	 its	 dose	 limiting	 side	 effect	 (Pasetto	 et	 al.,	 2006).	
Oxaliplatin	mechanism	of	action	 is	similar	 to	cisplatin	and	carboplatin,	 it	 forms	
cross-linking	 of	 DNA	 strands,	 however	 there	 are	 some	 differences	 in	 the	
pharmacology	 of	 the	 formation	 of	 these	 cross-links	 compared	 to	 cisplatin	
(Mishima	et	al.,	2002).	This	makes	it	a	candidate	as	an	alternative	treatment	to	
cisplatin	or	carboplatin	in	cases	of	platinum	drug	resistance.	Oxaliplatin	has	also	










There	 is	 a	 growing	 fear	 in	 the	 scientific	 community	 that	much	 of	 the	 research	
carried	 out	 in	 the	 various	 scientific	 fields	may	be	difficult,	 if	 not	 impossible	 to	
reproduce.	 The	 idea	 of	 this	 “reproducibility	 crisis”	 arose	 from	 the	 field	 of	
psychology	in	2011	when	a	psychology	research	paper	claiming	it	was	possible	to	










that	had	higher	 significance	 compared	 to	ones	 that	barely	 reached	significance	













In	 the	 field	 of	 cancer	 biology,	 the	 Reproducibility	 Project:	 Cancer	 Biology	 is	
underway.	 A	 collaboration	 between	 Science	 Exchange	 and	 the	 Center	 of	 Open	
Science,	they	are	attempting	to	replicate	a	subset	of	experimental	results	from	a	
selection	of	cancer	biology	papers	published	between	2010	and	2012	.	To	date,	15	
of	 the	replication	studies	have	been	completed:	 Important	parts	of	 the	original	
paper	was	reproduced	in	five	replication	studies	(Kandela	et	al.,	(2017);	Aird	et	
al.,	2017;	Shan	et	al.,	2017;	Showalter	et	al.,	2017;	Essex	et	al.,	2019);	another	five	
replication	 studies	 reproduced	 some	 parts	 but	 failed	 to	 reproduce	 some	 parts	
(Lewis	et	al.,	2018;	Vanden	Heuvel	et	al.,	2018;	Eaton	et	al.,	2018;	Kim	et	al.,	2018;	
Sheen	et	al.,	2019);	the	results	in	two	replication	studies	could	not	be	interpreted	









The	 terms	 “reproducibility”	 and	 “replication”	 seem	 to	 be	used	 interchangeably	
throughout	discussion,	and	perhaps	they	should	not	and	the	two	terms	should	be	
defined.	Reproducibility	would	describe	 the	ability	 to	reproduce	results	 from	a	
study	by	an	independent	research	group	using	equipment	and	specimens	(i.e.	cell	
lines)	from	different	sources	to	the	original.	An	example	of	this	has	already	been	
previously	 discussed.	 The	 CCLE	 and	 GDSC	 both	 independently	 required	
expression	profiles	for	a	collection	of	cancer	cell	lines	using	different	platforms.	
Expression	 levels	 between	 the	 cell	 lines	 shared	 by	 both	 studies	 correlated,	
suggesting	that	measuring	expression	of	cancer	cell	lines	is	reproducible,	despite	
this	 not	 being	 the	 case	 with	 their	 pharmacological	 data.	 Replication	 would	
describe	the	ability	to	replicate	the	original	research	exactly,	experimentally	and	
with	the	same	equipment	and	specimens.	So	perhaps	the	two	terms	should	not	be	



















to	 scientific	 reproducibility.	 Some	of	 the	main	 issues	with	cancer	 cell	 lines	and	





times	 led	 to	many	publications	 towards	 the	end	of	 the	20th	 century	 that	didn’t	





one	 to	 that	 described.	 Accepting	 that	 this	was	 a	 problem,	 introduction	 of	 new	
methods	 of	 authentication	 such	 as	 short	 tandem	 repeat	 analysis	 and	
authenticated,	 standardised	cell	 line	 collections	 such	as	 that	of	 the	ATCC	made	
available	have	all	but	abolished	this	problem,	but	there	is	still	evidence	of	research	
being	 carried	out	 recently	with	unauthenticated,	misidentified	 cancer	 cell	 lines	
(Huang	et	al.,	2017).	
	
Another	 issue	with	 cancer	 cell	 lines	 is	 the	 heterogeneity	within	 individual	 cell	
lines.	 It	 is	quite	possible	 that	cell	 lines	 that	go	 through	many	passages	develop	
mutations	other	than	those	from	parental	cell	lines	(Nelson-Rees	et	al.,	1976).	This	











sensitive	 in	 other	 research	 labs	 yet	 they	 have	 managed	 to	 develop	 quality	
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management	 procedures,	 such	 as	 improved	 electronic	 record	 keeping	 and	
auditing	of	labs	(Riedl	and	Dunn,	2013).		
	
Two	studies	offer	 interesting	 insight	 to	possible	problems	with	methodological	
procedure	 in	 labs.	 Smaldino	 and	 McElreath	 (2016)	 suggest	 that	 scientific	
methodology	evolves,	that	is	researchers	in	a	lab	will	inherit	work	practices	from	
that	lab	and	whoever	is	in	charge	of	that	lab,	and	then	begin	their	own	labs	with	
these	 inherited	 work	 practices.	 If	 researchers	 were	 rewarded	 primarily	 for	
publishing,	 then	 practices	 to	 promote	 research	 publication	 will	 have	 been	
“naturally	selected”	and	will	drive	their	own	lab.	This	is	no	bad	thing	of	course,	as	
these	methods	may	be	associated	with	greater	academic	success,	but	it	is	entirely	
possible	 that	 poor	 work	 practice	 can	 be	 “inherited”	 as	 well.	 Smaldino	 and	





the	model	 and	 positive	 findings	were	 easier	 to	 publish	 then	 negative	 findings.	
They	 concluded	 that	 the	 virtual	 labs	 shifted	 towards	 low-quality	 methods,	
widespread	unreliable	results	and	little	effort.	
	
Barnett	 et	 al.	 (2018)	 added	 to	 this	 model.	 They	 believe	 a	 “publish	 or	 peril”	




that	 if	 they	 implemented	auditing	1.35%	of	papers	published	 in	 the	model,	 the	
“competitive	spiral”	was	avoided	in	71%	of	simulations,	auditing	1.94%	avoided	
it	in	95%	of	simulations.	To	give	this	context,	by	not	adding	random	auditing	to	





aspects	 of	 the	 research	 environment.	 Assessing	 researchers	 properly	 has	 been	




the	 research	 environment,	 and	 suggest	 that	 more	 appropriate	 incentives	 for	
researchers	may	improve	the	research	standard.	They	concluded	that	many	things	
could	 help	 with	 better	 research	 assessment	 including	 implementing	 at	 the	
national	 level	 standardized	 assessment	 criteria	 that	 institutions	 could	 use	 to	
change	promotion	and	tenure	criteria	and	faculty	assessment.	They	also	admitted	
that	current	systems	reward	scientific	innovation	and	maybe	rewarding	scientists	
who	 excel	 with	 reproducible	 research	 (Flier,	 2017;	 Mogil	 and	 Macleod,	 2017;	
Topol,	2016).		
	




regards	 to	 the	 cell	 line	 misidentification,	 when	 asked	 if	 they	 would	 consider	
introducing	cell	 line	authentication	as	a	requirement	for	publication,	editors	be	
financial	suicide	and	reduce	the	amount	of	researchers	submitting	manuscripts	to	
their	 journal	 (Alston-Roberts	et	 al.,	 2010).	However,	 that	was	 a	 relatively	 long	
time	 ago,	 and	 Nature	 Publications	 has	 produced	 a	 formatting	 guide	
(https://www.nature.com/nature/for-authors/formatting-guide)	 for	
submissions	to	their	articles	and	has	adapted	it	to	make	research	and	results	as	




with	cooperation	between	all	parties	 involved	 in	 scientific	 research,	we	should	








publications	 can	 give	 a	 researcher	 an	 edge	 when	 applying	 for	 funding	 in	 an	















(Stroke	Unit	Trialists’	Collaboration,	2007).	Whether	 this	 is	 contributing	 to	 the	
reproducibility	crisis	or	not,	this	is	a	problem	that	should	be	addressed,	but	maybe	
it	 will	 take	 the	 journals	 being	 more	 accepting	 of	 so	 called	 “negative”	 results,	











may	 continue	 to	 collect	 or	 select	 data	 until	 previously	 nonsignificant	 results	
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become	significant	(Head	et	al.,	2015;	Wilcherts	et	al.,	2016).	Fanelli	believes	that	





One	 of	 the	 problems	 with	 declaring	 without	 doubt	 there	 is	 or	 isn’t	 a	
reproducibility	crisis,	is	that	there	is	relatively	little	quantitative	data	to	measure	















1. Investigating	 the	methods	 used	 by	 large	 pharmacogenomic	 screens	 and	
look	 to	 develop	 novel	 methods	 to	 use	 this	 large	 amount	 of	 data	 made	
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available	by	 the	multiple	screens.	A	 large	amount	of	data	 is	available,	 in	
amounts	 that	 are	 often	 not	 possible	 to	 collect	 in	 a	 single	 lab	 or	 group.	
Therefore,	I	believe	it	is	important	to	utilise	this	data	to	accompany,	guide	









three	 decades.	 It	 also	 used	 the	 same	 assay	 and	 experimental	 procedure	
over	that	time	period	so	any	variability	is	likely	to	be	due	to	human	error	
or	 the	 intrinsic	 variability	 that	 is	 present	 in	 biological	 systems.	 The	
questions	 surrounding	 the	 reproducibility	 crisis,	 as	 described	 in	 this	















platinum-based	 drugs	 cisplatin,	 carboplatin	 and	 oxaliplatin	 are	 in	 their	
pharmacological	behaviour	using	drug	sensitivity	data	for	60	cell	lines	in	the	NCI-











ovarian,	 lung,	 gastric,	 breast,	 and	 head	 and	 neck,	 but	 have	 been	 particularly	
successful	 at	 treating	 testicular	 cancer	 (Einhorn,	 1990).	 They	 cross-link	 DNA	
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is	 the	dose	 limiting	 side	effect	 for	 carboplatin	 and	neurotoxicity	 for	oxaliplatin	
(Pasetto	 et	 al.,	 2006).	 The	 side	 effects	 of	 carboplatin	 are	milder	 than	 those	 of	

























Annotated	 cell	 line	 data	 and	 all	 pharmacogenomic	 data	 (negative	 log10	 GI50	














Mean	Graphs	 for	 each	 drug	were	 obtained	 from	 the	 CellMiner	 resource.	 	 GI50	















Spearman	 correlations	 were	 determined	 for	 each	 drug-drug	 comparison	
(cisplatin-carboplatin,	 cisplatin-oxaliplatin,	 carboplatin-oxaliplatin)	 and	
displayed	 in	a	correlation	matrix	generated	using	R	package	corrplot	 (Wei	and	




























Using	 the	 cell	 line	 sensitivity	 status	 as	 determined	 using	 clinically	 relevant	
threshold,	a	heatmap	was	produced	using	R	package	ggplot2	(Wickham,	2016)	to	
display	cell	line	sensitivity	for	each	drug.	If	the	GI50	for	a	cell	line	was	below	or	














was	 compared	 using	 spearman’s	 rank-order	 correlation.	 A	 strong	 positive	
correlation	 was	 observed	 between	 the	 sensitivity	 profile	 of	 cisplatin	 and	
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Using	 the	 NCI-60	 resource	 CellMiner,	 Mean	 Graphs	 for	 the	 three	 compounds	




and	bars	 right	 of	 the	mean	 (+z-score)	 are	 classed	 sensitive.	This	 really	 sets	 an	
arbitrary	 threshold	of	 sensitivity	using	 the	mean,	 a	 cut-off	 such	as	 the	mean	 is	
unlikely	 to	 actually	 yield	 all	 sensitive	 and	 resistant	 cell	 lines	 but	 it	 is	 a	 good	




similarities.	 For	 virtually	 every	 tissue	 type	 the	 same	 pattern	 of	 sensitivity	 or	
resistance	is	observed.	Most	notably	for	colon	cell	lines	where	all	seven	cell	lines	
are	classed	as	resistant	to	the	compounds	and	for	leukaemia	and	ovarian	cell	lines	


























































































































































































































Using	 a	 z	 score	 of	 0	 as	 a	 threshold	 for	 sensitivity,	 cisplatin	 and	 carboplatin	
sensitivity	 and	 therefore	 mechanism	 of	 action	 were	 similar,	 oxaliplatin	 was	
different.	But	how	does	a	GI50	value	for	a	compound	and	a	cell	line	translate	to	a	
cancer	patient?	A	GI50	for	a	cell	line	that	is	classed	as	sensitive	(most	likely	relative	
to	other	cell	 lines	 in	 the	panel)	may	represent	a	 level	 that	would	be	toxic	 to	an	
actual	human.	So	perhaps	if	there	was	a	threshold	of	compound	sensitivity	that	
Chapter	2	 69	









or	 above	 (Gatti	 et	 al.,	 1999).	 If	 the	 treatment	 does	 not	 work	 at	 Cmax	 plasma	
concentration,	 the	 cancer	 should	be	 considered	 resistant	 to	 the	drug	 as	higher	





4.96uM	 oxaliplatin)	 54	 cell	 lines	were	 classed	 as	 sensitive	 to	 cisplatin	 and	 six	
resistant,	26	cell	lines	were	sensitive	to	carboplatin	and	34	resistant,	and	28	cell	
lines	 were	 sensitive	 to	 oxaliplatin	 and	 22	 resistant	 (no	 data	 for	 10	 cell	
lines)(Figure	 2.3B).	 The	 sensitivity	 profile	was	 very	 different	 to	 that	 using	 the	






between	 cisplatin	 and	 carboplatin	 while	 18	 of	 those	 had	 the	 same	 sensitivity	
profile	as	oxaliplatin	(Figure	2.3D).	Perhaps	more	strikingly,	17	cell	 lines	had	a	
sensitivity	allocation	unique	to	cisplatin	and	16	had	a	cell	 line	had	a	sensitivity	
allocation	 unique	 to	 carboplatin	 (Figure	 2.3D),	 both	 compared	 to	 only	 5	when	
considering	 the	 mean	 graph	 data	 (Figure	 2.3C).	 The	 sensitivity	 profiles	 for	





































































































































































































































































and	 carboplatin	 MOA,	 but	 there	 are	 also	 differences.	 As	 well	 as	 causing	 DNA	
damage	through	the	formation	of	DNA	crosslinks,	characteristic	of	platinum	drugs,	






that	of	oxaliplatin	 is	 further	confirmation	 that	oxaliplatin	MOA	differs	 from	the	
other	 two	 platinum	 drugs.	 The	 Mean	 Graphs	 can	 be	 treated	 like	 “compound	
fingerprints”	 as,	 although	 no	 two	 are	 identical,	 compounds	 with	 the	 same	 or	
similar	“fingerprint”	possess	the	same	or	similar	MOA.	The	COMPARE	algorithm	
available	 as	 a	 resource	 from	 the	 NCI-60	 actually	 uses	 these	 Mean	 Graphs	 to	
identify	 compounds	 with	 similar	 MOA	 to	 input	 compounds,	 and	 although	 not	
analysed	here,	oxaliplatin	has	been	used	in	the	COMPARE	algorithm	previously.	It	
was	determined,	using	COMPARE,	that	cisplatin	activity	was	similar	to	diamine-













lines	 show	 resistance	 to	 cisplatin	 and	 carboplatin,	 yet	 five	 of	 the	 seven	 are	



















The	 idea	was	 to	use	clinically	 relevant	 thresholds	 (Cmax)	as	 indicators	of	drug	
sensitivity.	 Interestingly,	 there	 was	 less	 concordance	 between	 cisplatin	 and	
carboplatin	in	this	analysis.	30/60	cell	lines	were	either	sensitive	or	resistant	to	
both	cisplatin	and	carboplatin.	This	did	not	differ	substantially	from	the	overlaps	
between	 cisplatin	 and	 oxaliplatin	 (29/50	 cell	 lines)	 as	 well	 as	 cisplatin	 and	
oxaliplatin	 (30/50	 cell	 lines).	 Hence,	 the	 efficacy	 profiles	 using	 clinical	
concentrations	provide	different	 results	 than	 the	correlation	of	dose	potencies.	
This	is	most	probably	the	case	because	even	closely	related	drugs	differ	in	their	









NCI-60	 confirmed	 the	 anticipated	 higher	 similarity	 between	 cisplatin	 and	


























































YM155-Adapted Cancer Cell Lines Reveal
Drug-Induced Heterogeneity and Enable the
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Abstract: Survivin is a drug target and its suppressant YM155 a drug candidate mainly investigated
for high-risk neuroblastoma. Findings from one YM155-adapted subline of the neuroblastoma cell line
UKF-NB-3 had suggested that increased ABCB1 (mediates YM155 e✏ux) levels, decreased SLC35F2
(mediates YM155 uptake) levels, decreased survivin levels, and TP53 mutations indicate YM155
resistance. Here, the investigation of 10 additional YM155-adapted UKF-NB-3 sublines only confirmed
the roles of ABCB1 and SLC35F2. However, cellular ABCB1 and SLC35F2 levels did not indicate
YM155 sensitivity in YM155-naïve cells, as indicated by drug response data derived from the Cancer
Therapeutics Response Portal (CTRP) and the Genomics of Drug Sensitivity in Cancer (GDSC)
databases. Moreover, the resistant sublines were characterized by a remarkable heterogeneity.
Only seven sublines developed on-target resistance as indicated by resistance to RNAi-mediated
survivin depletion. The sublines also varied in their response to other anti-cancer drugs. In conclusion,
cancer cell populations of limited intrinsic heterogeneity can develop various resistance phenotypes
in response to treatment. Therefore, individualized therapies will require monitoring of cancer cell
evolution in response to treatment. Moreover, biomarkers can indicate resistance formation in the
acquired resistance setting, even when they are not predictive in the intrinsic resistance setting.
Keywords: acquired drug resistance; biomarkers; therapy monitoring; neuroblastoma; BIRC5;
survivin; intrinsic drug resistance
1. Introduction
Sepantronium bromide (YM155) was introduced as an anti-cancer drug candidate that inhibits
expression of the BIRC5 gene, which encodes the protein survivin [1]. In the meantime, YM155 has been
suggested to exert additional and/or alternative mechanisms of anticancer actions, including induction
Cancers 2020, 12, 1080; doi:10.3390/cancers12051080 www.mdpi.com/journal/cancers
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of DNA damage, inhibition of NFB signaling, induction of death receptor 5 expression, and/or
suppression of MCL-1, XIAP, cIAP-1/2, BCL-2, BCL-XL, FLIP, EGFR, and/or mTORC [2–13].
A number of studies have investigated the potential of YM155 against neuroblastoma cells [14–17].
Neuroblastoma is the most common extracranial solid childhood tumor. Treatment outcomes in
high-risk neuroblastoma patients remain unsatisfactory. About 50% of these patients relapse and
have a 5-year-survial rate below 10% [18–21]. We have recently shown that suppression of survivin
expression is the main mechanism through which YM155 exerts its anti-neuroblastoma e↵ects [16].
Notably, the New Drug Development Strategy (NDDS, a project of Innovative Therapies for Children
with Cancer, the European Network for Cancer Research in Children and Adolescents, and the
International Society of Paediatric Oncology Europe Neuroblastoma) has categorized survivin as a
high priority drug target in neuroblastoma and YM155 as a high priority drug [22].
The formation of acquired resistance is a central problem in (metastasized) cancer diseases that need
to be treated by systemic drug therapy. Although many cancers initially respond well to therapy, resistance
formation is common, and cures are rare [23]. Hence, biomarkers that indicate early therapy failure are
needed to adapt therapies if resistance emerges. Liquid biopsies (e.g., circulating tumor cells) enable the
monitoring of cancer cell evolution in patients with ever more detail [24]. However, the translation of the
resulting information into improved therapies is hampered by a lack of understanding of the processes
underlying acquired resistance formation and, in turn, a lack of biomarkers.
Most studies focus on biomarkers that indicate whether a certain cancer cell (population) is
likely to respond to a certain treatment but not on biomarkers that indicate early that a current
therapy has stopped working. This also applies to the previous studies that investigated the e cacy
of YM155 in neuroblastoma [14,15,17]. However, it is known that intrinsic and acquired resistance
mechanisms may substantially di↵er [25–27]. Using a single YM155-adapted neuroblastoma cell line,
we identified increased ABCB1 (also known as P-glycoprotein or MDR1) expression, decreased SLC35F2
(solute carrier family 35 member F2) expression, decreased survivin expression, and loss-of-p53 function
as potential markers of resistance formation to YM155 [16]. Given the tremendous (intra-tumor)
heterogeneity in cancer [28], it is likely that the processes, which result in acquired resistance formation,
are equally complex. If so, then a larger number of models of acquired resistance to a certain drug will
be needed to adequately address the complexity of the resistance formation process.
To test this hypothesis, we here established and characterized 10 further YM155-adapted UKF-NB-3
neuroblastoma cell lines. Moreover, acquired resistance models may provide information that cannot
be gained from the comparison of non-adapted cell lines with a varying resistance status. To investigate
whether this is the case, the findings from the YM155-adapted UKF-NB-3 sublines were compared to
data from the two large pharmacogenomics screens Genomics of Drug Sensitivity in Cancer (GDSC)
and Cancer Therapeutic Response Portal (CTRP), which use non-adapted cancer cell lines [29,30],
whether we can obtain information from our acquired resistance models that cannot be identified
from traditional approaches using non-adapted cell lines. We also analyzed YM155 response data
from the two large pharmacogenomics screens Genomics of Drug Sensitivity in Cancer (GDSC) and
Cancer Therapeutic Response Portal (CTRP) [29,30]. We found a remarkable heterogeneity between
the individual sublines, although they all were derived from the same parental cell line. An increase in
cellular ABCB1 levels and/or a decrease in SLC35F2 levels indicate resistance formation to YM155,
although the ABCB1 and/or SLC35F2 levels cannot be used to infer YM155 sensitivity in YM155-naïve
cell lines. The use of the panel of YM155-adapted cell lines further enabled us to show that the cellular
survivin levels and the TP53 status do not reliably indicate resistance formation.
2. Results
2.1. YM155-Adapted UKF-NB-3 Sublines Display Pronounced YM155 Resistance
All YM155-adapted UKF-NB-3 sublines displayed pronounced YM155 resistance (Figure 1,
Table S1). The YM155-adapted UKF-NB-3 sublines displayed between 38- and 76-fold increased YM155
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IC50 values and between 30- and 135-fold increased IC90 values relative to UKF-NB-3 (Table S1).
Representative photos of the morphology of the project cell lines are presented in Figure S1 and the
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Figure 1. YM155 concentrations that reduce the viability of UKF-NB-3 and its YM155-adapted sublines
by 50% (IC50) or 90% (IC90) as determined by MTT assay after 120 h of incubation. The sublines
display significantly increased YM155 resistance. Numerical values are presented in Table S1. * p < 0.05
relative to UKF-NB-3.
2.2. The Cellular TP53 Status is Not a Reliable Indicator of YM155 Sensitivity
Originally, the cellular TP53 status was described to not directly influence the anticancer action of
YM155 [31]. In agreement, the analysis of the Genomics of Drug Sensitivity in Cancer (GDSC) and
Cancer Therapeutics Response Portal (CTRP) databases did not indicate di↵erences in the YM155
sensitivity between cell lines in dependence on their TP53 status (wild-type or mutant) (Figure 2).
 
Figure 2. YM155 sensitivity in TP53 wild-type and TP53 mutant cancer cell lines based on the analysis of
GDSC and CTRP data, both determined across all investigated cancer types/cell lines (GDSC, p = 0.458;
CTRP, p = 0.216) and in a neuroblastoma-specific analysis (GDSC, p = 0.922; all 12 neuroblastoma cell
lines in the CTRP harbor wild-type TP53). The comparisons did not reveal significant di↵erences.
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However, the activation of p53 signaling seems to be involved in the anticancer mechanism of
action of YM155 at least in some cancer cells. We have previously shown in neuroblastoma cells that
YM155 activates p53 signaling, that p53 activation using MDM2 inhibitors enhances the YM155 e↵ects,
and that p53 depletion reduces cancer cell sensitivity to YM155 [15]. In addition, a YM155-adapted
UKF-NB-3 subline harbored a TP53 mutation [16]. However, all 10 YM155-adapted UKF-NB-3 sublines
that we investigated here displayed wild-type TP53 as indicated by TP53 next-generation sequencing.
The cellular p53 levels also did not di↵er consistently between UKF-NB-3 and its YM155-resistant
sublines (Figure S2). The YM155-resistant UKF-NB-3 sublines remained similarly sensitive to the
MDM2 inhibitor and p53 activator nutlin-3 as UKF-NB-3 (Table S2). Hence, our findings do not
suggest that YM155 adaption is generally associated with a loss of p53 function in neuroblastoma cells.
The cellular TP53 status is not a reliable indicator of YM155 sensitivity, neither in the intrinsic nor in
the acquired resistance setting.
2.3. Cellular Survivin Levels Do Not Reliably Indicate YM155 Response
Some studies suggested cancer cells with high survivin levels to be particularly sensitive to
YM155 [31–33]. However, other studies failed to detect an association between the cellular survivin
status and YM155 activity [16,34]. When we compared the YM155 sensitivity between cancer cell lines
with high and low survivin expression, we found statistically significant di↵erences across all cell
lines in the GDSC and CTRP datasets but not across the neuroblastoma cell lines (Figure 3). It was not
possible to predict whether a certain cell line was sensitive to YM155 based on the cellular survivin
level (Figure 3).
 
Figure 3. YM155 sensitivity in cell lines characterized by high or low survivin expression based on
the analysis of GDSC and CTRP data, both determined across all investigated cancer types/cell lines
(GDSC, p = 0.048; CTRP, p < 0.001) and in a neuroblastoma-specific analysis (GDSC, p = 0.425; CTRP, p
= 0.699). Across all cell lines, high survivin expression was associated with increased YM155 sensitivity,
but the YM155 sensitivity of individual cell lines could not be predicted based on the survivin levels.
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Notably, a YM155-adapted UKF-NB-3 subline had previously displayed reduced survivin levels
relative to the parental cell line [16]. However, the analysis of the 10 additional YM155-adapted
UKF-NB-3 sublines in this study revealed that resistance acquisition to YM155 was not associated with
a consistent change in the survivin expression patterns (Figure S3).
2.4. Acquired YM155 Resistance is Associated with Decreased Sensitivity to Survivin Depletion
Our previous findings suggested that YM155 predominantly exerts its antineuroblastoma e↵ects
via suppression of survivin expression [16]. Seven of the 10 YM155-adapted UKF-NB-3 sublines (I, III,
V, VII, VIII, IX, X) displayed decreased sensitivity to siRNA-mediated survivin depletion, indicating
that they developed on-target resistance. However, two sublines were similarly sensitive as parental
UKF-NB-3 cells (II, VI), and one subline (IV) was more sensitive to survivin depletion (Figure 4,
Figure S4). This shows that the YM155 resistance mechanisms di↵er between the individual UKF-NB-3
sublines. Notably, the viability of all sublines is still a↵ected by survivin depletion, which shows that
they have retained some level of survivin dependence.
 
Figure 4. E↵ects of siRNA-mediated BIRC5/survivin depletion on the viability of UKF-NB-3 and
its YM155-adapted sublines. Western blots confirm reduced survivin levels 48 h post-transfection.
Viability of cells transduced with siRNA directed against BIRC5/survivin or non-targeting siRNA was
determined relative to untreated control cells 168 h post transfection by MTT assay. The cell lines
displayed varying levels of sensitivity to survivin depletion. * p < 0.05 relative to untreated cells.
Uncropped blots are shown in Figure S4.
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2.5. Relevance of Cellular ABCB1 and SLC35F2 Levels in the Context of YM155 Resistance
Increased cellular ABCB1 (mediates YM155 e✏ux) levels and decreased SLC35F2 (mediates cellular
YM155 uptake) levels have previously been identified as important YM155 resistance
mechanisms [14,16,17,35]. To further investigate the relationship between ABCB1 and SLC35F2
levels and YM155 sensitivity, we compared the YM155 sensitivity in cell lines that displayed low or
high expression of the respective genes using GDSC and CTRP data. In agreement with previous
data, high ABCB1 expression (Figure 5) and low SLC35F2 expression (Figure 6) were associated with
reduced YM155 sensitivity. When we used transcriptomics data from the GDSC and CTRP to correlate
the expression of all genes with YM155 sensitivity, ABCB1 ranked as the gene whose expression was
most strongly correlated to the YM155 AUC (area under the curve, unit used to quantify the drug
response) (Table 1) in the GDSC and CTRP. SLC35F2 expression was most strongly inversely correlated
to the YM155 AUC (Table 2) in both data sets. There were no further overlaps among the top 10 genes
between the two databases (Tables 1 and 2). However, the YM155 sensitivity of a certain cell line could
not be reliably predicted based on the cellular ABCB1 and/or SLC35F2 levels (Figures 5 and 6).
 
Figure 5. YM155 sensitivity in cancer cell lines characterized by high or low ABCB1 expression based
on the analysis of GDSC and CTRP data, both determined across all investigated cancer types/cell lines
(GDSC, p < 0.001; CTRP, p < 0.001) and in a neuroblastoma-specific analysis (GDSC, p = 0.006; CTRP,
p = 0.04). High ABCB1 expression was associated with decreased YM155 sensitivity, but the YM155
sensitivity of individual cell lines could not be predicted based on the ABCB1 levels.
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Figure 6. YM155 sensitivity in cancer cell lines characterized by high or low SLC35F2 expression based
on the analysis of GDSC and CTRP data, both determined across all investigated cancer types/cell lines
(GDSC, p < 0.001; CTRP, p < 0.001) and in a neuroblastoma-specific analysis (GDSC, p = 0.033; CTRP,
p = 0.310). High SLC35F2 expression was associated with increased YM155 sensitivity, but the YM155
sensitivity of individual cell lines could not be predicted based on their SLC35F2 levels.
Table 1. Top 10 genes whose expression is most strongly correlated with the YM155 AUC in the
Genomics of Drug Sensitivity in Cancer (GDSC) database and the Cancer Therapeutics Response Portal
(CTRP) as indicated by the Pearson correlation coe cient.
GDSC CTRP
Gene Correlation Coe cient FDR 1 Gene Correlation Coe cient FDR
ABCB1 0.3792069 2.82 ⇥ 10 6 ABCB1 0.3624858 2.70 ⇥ 10 6
FABP1 0.2972293 5.64 ⇥ 10 6 CST3 0.3603422 5.39 ⇥ 10 6
CDX2 0.2927057 8.46 ⇥ 10 6 AKR1C3 0.3503176 8.09 ⇥ 10 6
DDC 0.2922995 1.13 ⇥ 10 5 EPS8 0.3453892 1.08 ⇥ 10 5
CDH17 0.2652645 1.41 ⇥ 10 5 ABHD2 0.3309384 1.35 ⇥ 10 5
ANKS4B 0.2637047 1.97 ⇥ 10 5 S100A6 0.3229691 1.62 ⇥ 10 5
MYO1A 0.2626518 2.26 ⇥ 10 5 ATP1B1 0.3111308 1.89 ⇥ 10 5
PHGR1 0.2609317 2.54 ⇥ 10 5 CD63 0.310712 2.16 ⇥ 10 5
A1CF 0.252912 2.82 ⇥ 10 5 AKR1C1 0.3073306 2.43 ⇥ 10 5
GUCY2C 0.2513048 3.10 ⇥ 10 5 ACVR1 0.30124 9.44 ⇥ 10 5
1 false discovery rate.
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Table 2. Top 10 genes whose expression is most strongly inversely correlated with the YM155 AUC in
the Genomics of Drug Sensitivity in Cancer (GDSC) database and the Cancer Therapeutics Response
Portal (CTRP) as indicated by the Pearson correlation coe cient.
GDSC CTRP
Gene Correlation Coe cient FDR 1 Gene Correlation Coe cient FDR
SLC35F2  0.2643809 1.69 ⇥ 10 5 SLC35F2  0.3868041 9.17 ⇥ 10 5
ALKBH8  0.2042557 0.000121 CD19  0.349156 8.90 ⇥ 10 5
CWF19L2  0.1926243 0.000180 CD79B  0.346035 8.63 ⇥ 10 5
RCSD1  0.1855956 0.000226 SPIB  0.341887 8.36 ⇥ 10 5
P2RY8  0.1834937 0.000257 SNX22  0.338893 8.09 ⇥ 10 5
RGS19  0.1831031 0.000259 TCL1A  0.338393 7.82 ⇥ 10 5
FLI1  0.1825892 0.000268 LOC100130458  0.337940 7.55 ⇥ 10 5
VAV1  0.1819569 0.000273 BLK  0.330471 7.28 ⇥ 10 5
ATM  0.1816322 0.000276 CD79A  0.324465 7.01 ⇥ 10 5
ARHGAP19  0.1813872 0.000282 VPREB3  0.322878 6.74 ⇥ 10 5
1 false discovery rate.
All YM155-adapted UKF-NB-3 sublines displayed increased ABCB1 levels relative to UKF-NB-3
(Figure 7, Figure S5). Acquired YM155 resistance was also generally associated with decreased SLC35F2
levels, in particular in the sublines I, IV, VI, and X (Figure 7, Figure S5). This indicates that increased
ABCB1 levels and decreased SLC35F2 levels have potential as biomarkers, indicating YM155 resistance
formation in response to YM155-based therapies, although cellular ABCB1 and SLC35F2 levels do not

































































Figure 7. Representative Western blots indicating cellular levels of ABCB1 and SLC35F2 in UKF-NB-3
and YM155-adapted UKF-NB-3 sublines. YM155-adapted sublines are typically characterized by
increased ABCB1 levels and decreased SLC35F2 levels. Uncropped blots are shown in Figure S5.
2.6. YM155-Adapted UKF-NB-3 Cells Remain Sensitive to DNA Damage Caused by Irradiation and Cytotoxic Drugs
YM155 has been proposed to exert its anticancer e↵ects via the induction of DNA damage in
some experimental systems [3,5,35,36]. To study whether the acquisition of YM155 resistance was
associated with a generally increased resistance to DNA damage, UKF-NB-3 and its YM155-adapted
UKF-NB-3 sublines were irradiated at a dose range of one to five Gy. None of the YM155-adapted
UKF-NB-3 sublines displayed substantially reduced sensitivity to irradiation relative to UKF-NB-3
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(Figure 8). Moreover, none of the YM155-resistant UKF-NB-3 sublines displayed reduced sensitivity to
cisplatin (causes DNA crosslinks) or topotecan (topoisomerase I inhibitor), which cause DNA damage
by di↵erent mechanisms (Figure 8, Table S2). There was also no coherent increase in resistance to the
nucleoside analogue gemcitabine (Figure 8, Table S2). These data do not suggest that the activity of
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Figure 8. Sensitivity of UKF-NB-3 and its YM155-adapted sublines to irradiation and DNA-damaging
drugs. The radiation response was determined 72 h after irradiation with 1, 3, or 5Gy by MTT assay.
Drug concentrations that reduce cell viability by 50% (IC50) were determined by MTT assay after 120
h of incubation. The YM155-adapted sublines did not display increased resistance to DNA damage
induced by radiation or the drugs cisplatin, gemcitabine, or topotecan. * p < 0.05 relative to UKF-NB-3.
2.7. Heterogeneity among YM155-Adapted UKF-NB-3 Sublines
While the YM155-adapted UKF-NB-3 sublines displayed limited heterogeneity in response
to treatment with cisplatin and topotecan, remarkable di↵erences in the gemcitabine IC50s were
detected (Figure 8, Table S2). The fold di↵erence between the YM155-adapted subline with the
lowest gemcitabine IC50 (V, 0.12 ng/mL) and the subline with the highest IC50 (VIII, 0.65 ng/mL) was
5.4-fold. This heterogeneity is in agreement with the up to 29-fold di↵erence observed in the cell
viability in response to BIRC5/survivin depletion between the most sensitive (IV) and the most resistant
(VII) subline (Figure 4). Resistance profiles to the destabilizing tubulin-binding agent vincristine
also revealed a substantial heterogeneity between the YM155-resistant UKF-NB-3 sublines (Figure 9,
Table S2), resulting in a fold di↵erence of 127 between subline VI (vincristine IC50: 714 ng/mL) and
subline IX (vincristine IC50: 5.6 ng/mL) (Table S2).
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Figure 9. Vincristine concentrations that reduce cell viability by 50% (IC50) were determined by MTT
assay after 120 h of incubation. YM155-adapted sublines consistently displayed decreased vincristine
sensitivity relative to UKF-NB-3. The vincristine IC50 values varied considerably. * p < 0.05 relative
to UKF-NB-3.
3. Discussion
In a previous study, a YM155-adapted subline of the neuroblastoma cell line UKF-NB-3 was
characterized by increased cellular ABCB1 levels, decreased SLC35F2 and survivin levels, and a
TP53 mutation [16]. Here, we systematically investigated the relevance of cellular ABCB1, SLC35F2,
and survivin levels as well as the TP53 status as potential biomarkers of YM155 resistance formation
in the intrinsic resistance setting, using data derived from the GDSC and CTRP databases [29,30],
and in the acquired resistance setting, using an additional set of 10 YM155-adapted UKF-NB-3 sublines,
which were established in independent experiments.
Increased ABCB1 expression (mediates YM155 e✏ux) and decreased SLC35F2 expression
(mediates cellular YM155 uptake) were identified as YM155 resistance mechanisms in panels
of YM155-naïve cell lines that displayed varying levels of these proteins and in functional
studies [14,16,17,37], which was further supported by our analysis of GDSC and CTRP data [29,30].
Despite their roles in determining YM155 resistance, however, cellular ABCB1 or SLC35F2 levels
did not enable the prediction of whether an individual cell line would be sensitive to YM155 or not.
The YM155-adapted UKF-NB-3 cell lines generally displayed elevated cellular ABCB1 levels and
reduced SLC35F2 levels relative to UKF-NB-3. Hence, an increase in the cellular ABCB1 levels and/or a
decrease in the SLC35F2 levels have potential as biomarkers that indicate resistance formation, even
though the respective cellular levels do not reliably predict the YM155 response in YM155-naïve cells.
Initially, the TP53 status was reported not to influence the anticancer e↵ects of YM155 [31],
which was further supported by our analysis of GDSC and CTRP data. In neuroblastoma cells,
however, YM155 induced p53 signaling, p53 depletion reduced YM155 sensitivity, and a YM155-adapted
UKF-NB-3 subline harbored a TP53 mutation [16]. Here, all 10 YM155-adapted UKF-NB-3 sublines
retained wild-type TP53. Thus, the role of p53 seems to depend on the individual cellular context.
Neither the cellular TP53 status nor the formation of TP53 mutations can currently be considered as
valid biomarkers for YM155 therapies.
The relevance of cellular survivin levels for cancer cell sensitivity to YM155 is not clear [16,31–35].
Our analysis of GDSC and CTRP data indicated that high survivin (BIRC5) expression was associated
with increased YM155 sensitivity. However, it was not possible to infer the YM155 sensitivity of a
particular cell line based on its survivin status. Reasons for this may include that survivin is not in all
cell lines the major therapeutic target of YM155 as it is in neuroblastoma cells [1–12,16,36] and/or that
o↵-target resistance mechanisms, such as ABCB1 and SLC35F2 expression, may a↵ect YM155 e cacy
independently of the survivin status [14,16,17,35].
The YM155-adapted UKF-NB-3 sublines displayed various survivin levels, demonstrating that
resistance formation to YM155 is also not associated with a consistent change in cellular survivin levels.
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Seven of the YM155-adapted cell lines displayed on-target resistance as indicated by reduced sensitivity
to RNAi-mediated BIRC5/survivin depletion relative to parental UKF-NB-3 cells, further confirming
that survivin is a target of YM155 in neuroblastoma cells. However, cellular survivin levels do not
represent a reliable biomarker of resistance formation to YM155.
While YM155 was described to act via the induction of DNA damage in some cancer types [3,5,35,
36], our previous results did not indicate a causative role of DNA damage induction in the anticancer
e↵ects of YM155 against neuroblastoma cells [16]. YM155 resistance formation in the YM155-adapted
neuroblastoma cell lines was also not associated with generally decreased sensitivity to radiation or
DNA damage caused by cisplatin (causes DNA crosslinks), gemcitabine (nucleoside analogue), or
topotecan (topoisomerase I inhibitor). This indicates that YM155 resistance formation in neuroblastoma
cells is not generally associated with an increased resistance to DNA damage induction.
In this study, the use of multiple models of acquired resistance enabled insights that could not
be gained from just one drug-adapted subline. The previous investigation of one YM155-resistant
UKF-NB-3 subline had suggested that changes in the cellular TP53 status and survivin levels indicate
resistance formation [16], which was not confirmed in our current panel of 10 YM155-adapted
UKF-NB-3 sublines. Moreover, the use of multiple sublines provided a novel glimpse into the
significant heterogeneity of the resistance formation process, even though all resistant sublines were
derived from the same parental cell line. Only 7 of the 10 sublines developed on-target resistance
mechanisms as indicated by reduced sensitivity to survivin depletion. The sublines also showed
substantial variation in their sensitivity to irradiation (up to 7-fold di↵erence at 5Gy), gemcitabine
(up to 5-fold), and vincristine (up to 127-fold). Notably, a much higher heterogeneity would be expected
in the clinical situation, in which tumors are already characterized by much higher heterogeneity than
cancer cell lines and in which combination therapies are common.
4. Materials and Methods
4.1. Cells
The MYCN-amplified neuroblastoma cell line UKF-NB-3 was established from a bone marrow
metastasis of a stage IV neuroblastoma patient [38]. Ten YM155-resistant UKF-NB-3 sublines were derived
from the resistant cancer cell line (RCCL) collection (https://research.kent.ac.uk/industrial-biotechnology-
centre/the-resistant-cancer-cell-line-rccl-collection/). They were established by adaptation of UKF-NB-3
cells (passage 87) to growth in the presence of YM155 20nM by previously described methods [39] and
designated as UKF-NB-3rYM15520nMI to UKF-NB-3rYM15520nMX. All cells were propagated in IMDM
supplemented with 10 % FBS, 100 IU/mL penicillin, and 100 µg/mL streptomycin at 37  C. Cells were
routinely tested for mycoplasma contamination (PlasmoTest™, Mycoplasma Detection kit, InvivoGen,
Toulouse, France) and authenticated by short tandem repeat profiling.
To determine doubling times, 2 ⇥ 104 cells per well were plated into 6-well plates, incubated at
37  C and 5% CO2, and counted after 1, 2, 3, 5, and 7 days using a Neubauer chamber. Doubling times
were then calculated using http://www.doubling-time.com/compute.php, which uses the equation:
Doubling time = duration ⇥ log(2)/log(final cell number)   log(initial cell number).
4.2. Viability Assay
Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) dye reduction assay after 120 h of incubation modified as described previously [39].
Cells (2 ⇥ 104/100 µL per well in 96-well plates) were incubated in the presence or absence of drug
for 120 h. Then, 25 µL of MTT solution (2 mg/mL (w/v) in PBS) were added per well, and the plates
were incubated at 37  C for an additional 4 h. After this, the cells were lysed using 100 µL of a
bu↵er containing 20% (w/v) sodium dodecylsulfate and 50% (v/v) N,N-dimethylformamide with the
pH adjusted to 4.7 at 37  C for 4 h. Absorbance was determined at 570 nm for each well using a
96-well multiscanner. After subtraction of the background absorption, the results were expressed as the
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percentage viability relative to control cultures that received no drug. Drug concentrations that inhibited
cell viability by 50% (IC50) or 90% (IC90) were determined using CalcuSyn (Biosoft, Cambridge, UK).
4.3. TP53 Next-Generation Sequencing
TP53 next-generation sequencing was performed as previously described [16]. All coding exonic
and flanking intronic regions of the human TP53 gene were amplified from genomic DNA with
Platinum™ Taq DNA polymerase (Life Technologies) by multiplex PCR using two primer pools with
12 non-overlapping primer pairs each, yielding approximately 180 bp amplicons. Each sample was
tagged with a unique 8-nucleotide barcode combination using 12 di↵erently barcoded forward and
eight di↵erently barcoded reverse primer pools. Barcoded PCR products from up to 96 samples were
pooled, purified, and an indexed sequencing library was prepared using the NEBNext® ChIP-Seq
Library Prep Master Mix Set for Illumina in combination with NEBNext® Multiplex Oligos for Illumina
(New England Biolabs). The quality of sequencing libraries was verified on a Bioanalyzer DNA High
Sensitivity chip (Agilent) and quantified by digital PCR. 2 ⇥ 250 bp paired-end sequencing was carried
out on an Illumina MiSeq (Illumina) according to the manufacturer’s recommendations at a mean
coverage of 300⇥.
Read pairs were demultiplexed according to the forward and reverse primers and subsequently
aligned using the Burrows-Wheeler Aligner against the Homo sapiens Ensembl reference (rev. 79).
Overlapping mate pairs where combined and trimmed to the amplified region. Coverage for each
amplicon was calculated via SAMtools (v1.1) [40]. To identify putative mutations, variant calling was
performed using SAMtools in combination with VarScan2 (v2.3.9) [41]. Initially, SAMtools was used to
create pileups with a base quality filter of 15. Duplicates, orphan reads, unmapped, and secondary
reads were excluded. Subsequently, Varscan2 was applied to screen for SNVs and InDels separately,
using a low-stringency setting with minimal variant frequency of 0.1, a minimum coverage of 20,
and a minimum of 10 supporting reads per variant to account for cellular and clonal heterogeneity.
Minimum average quality was set to 20 and a strand filter was applied to minimize miscalls due to
poor sequencing quality or amplification bias. The resulting list of putative variants was compared
against the IARC TP53 (R17) database to check for known p53 cancer mutations.
4.4. Western Blot
Cells were lysed using Triton-X-100 sample bu↵er, and proteins were separated by SDS-PAGE.
Detection occurred by using specific antibodies against  -actin (1:5000 dilution, Biovision through
BioCat GmbH, Heidelberg Germany; secondary antibody: IRDye® 800CW Goat anti-Mouse IgG,
dilution 1:25,000, Li-Cor Biosciences, Lincoln, NE, USA), SLC35F2 (1:200, Santa Cruz Biotechnology,
Dallas, TX, USA; secondary antibody: IRDye® 800CW Goat anti-Mouse IgG, dilution 1:25,000,
Li-Cor Biosciences, Lincoln, NE, USA), GAPDH (1:4000, Trevigen via Bio-Techne GmbH, Wiesbaden,
Germany; secondary antibody: IRDye® 800CW Goat anti-Rabbit IgG, dilution 1:25,000, Li-Cor
Biosciences), ABCB1 (1:1,000, Cell Signaling via New England Biolabs, Frankfurt, Germany; secondary
antibody: IRDye® 800CW Goat anti-Rabbit IgG, dilution 1:25,000, Li-Cor Biosciences), p53 (1:1000,
Enzo Life Sciences, Lörrach, Germany; secondary antibody: IRDye® 800CW Goat anti-Mouse IgG,
dilution 1:25,000, Li-Cor Biosciences), and survivin (1:500, R&D Systems, Minneapolis, MN, USA;
secondary antibody: IRDye® 800CW Goat anti-Rabbit IgG, dilution 1:25,000, Li-Cor Biosciences).
Protein bands were visualized by laser-induced fluorescence using infrared scanner for protein
quantification (Odyssey, Li-Cor Biosciences) and Image Studio Ver. 5.2 software (Li-Cor Biosciences)
for densitometric analyses.
4.5. RNA Interference Experiments
Transient depletion of BIRC5/survivin was achieved using synthetic siRNA oligonucleotides
(ON-TARGETplus SMARTpool) from Dharmacon (Lafayette, CO, USA). Non-targeting siRNA
(ON-TARGETplus SMARTpool) was used as negative control. Cells were transfected by electroporation
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using the NEON Transfection System (Invitrogen, Darmstadt; Germany) according to the manufacturer
protocol. Cells were grown to 60–80% confluence, trypsinised, and 1.2 ⇥ 106 cells were re-suspended
in 200 µL of resuspension bu↵er R including 2.5 µM siRNA. The electroporation was performed using
two 20 ms pulses of 1400 V. Subsequently, the cells were transferred into cell culture plates or flasks,
containing pre-warmed cell culture medium. During the set-up of the experiments, the SMARTpool
was compared to two individual siRNAs (target sequences: GCAAAGGAAACCAACAAUA,
GGAAAGGAGAUCAACAUUU) (Figure S6).
4.6. Irradiation Procedure
In 96-well cell culture plates, 104 cells per well were irradiated at room temperature
(Greiner, Bio-ONE GmbH, Frickenhausen, Germany) with single doses of X-rays ranging from 1
to 5 Gy using a linear accelerator (SL 75/5, Elekta, Crawley, UK) with 6 MeV photons/100 cm
focus–surface distance with a dose rate of 4.0 Gy/min. Sham-irradiated cultures were kept at room
temperature in the X-ray control room while the other samples were irradiated.
4.7. Analysis of Data Derived from Large Pharmacogenomic Studies
All data (including drug response area under curve (AUC) data for YM-155-treated cancer cell lines,
basal gene-expression for ABCB1, BIRC5 (the gene that encodes survivin), and SLC35F2, and genomic
alterations of p53) in this study were obtained from two online resources: Version 2 of the Cancer
Therapeutics Response Portal (CTRP v2) data [29,42] were obtained from the Cancer Target Discovery
and Development (CTD2) data portal (ocg.cancer.gov/programs/ctd2/data-portal). The Genomics of
Drug Sensitivity in Cancer (GDSC) data were obtained from www.cancerrxgene.org [43,44].
The CTRP contains ABCB1, BIRC5, and SLC35F2 expression data for 823 cell lines and YM-155
AUC data for 715 cell lines. For 703 cell lines (including 12 neuroblastoma cell lines), gene expression
data and YM155 AUC values were available. Whole exome sequencing (WES) data was available for
546 of the cell lines for which YM-155 sensitivity data was also available (including 11 neuroblastoma
cell lines).
The GDSC contains ABCB1, BIRC5, and SLC35F2 expression data for 1019 cell lines and YM155
AUC data for 945 cell lines. Expression data and WES data were available for all 945 cell lines with
YM-155 sensitivity data (including 30 neuroblastoma cell lines).
Data processing was performed using Perl version 5.26.0, and R statistical packages version 3.3.2.
Cell lines were determined to display either high or low expression for each gene using the median
gene expression as a threshold (i.e., low expression < =median expression, high expression >median
expression). Box plots indicating the YM-155 sensitivity in cell lines that display low or high expression
of a certain gene or wild-type or mutant TP53 were produced using the ggplot2 package [45] in R.
Statistical tests were carried out in R and included Wilcoxon rank-sum test [46] and Pearson’s
correlation [47]. Correction for multiple comparisons was performed using the Benjamini–Hochberg
procedure [37].
4.8. Statistics
Results are expressed as mean ± S.D. of at least three experiments. Comparisons between the
means of two sample groups were performed using Student’s t-test. The means of three or more
sample groups were compared by one-way ANOVA followed by the Student–Newman–Keuls test.
P values lower than 0.05 were considered to be significant.
5. Conclusions
Our data revealed a high phenotypic heterogeneity among a panel of 10 YM155-resistant sublines
of the neuroblastoma cell line UKF-NB-3. This heterogeneity is of conceptual importance, because it
shows that even a defined cancer cell population of limited intrinsic heterogeneity can develop
various resistance mechanisms and phenotypes in response to treatment. From a clinical perspective,
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this means that the close monitoring of cancer cell evolution in response to therapy will have to become
an essential part of the design of individualized therapies. Notably, such insights can only be gained
from preclinical model systems, such as drug-adapted cancer cell lines, which enable the repeated
adaptation of a given cancer cell population to the same treatment but not from clinical material as
every patient can only be treated once.
Our findings also demonstrate that biomarkers can indicate resistance formation, even when
they do not enable the prediction of drug sensitivity in therapy-naïve cancer cells. Hence, the
use of biomarkers di↵ers between the intrinsic and the acquired resistance setting, and pre-clinical
models of acquired drug resistance are needed for the identification of such biomarkers that herald
resistance development.
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The	 aim	 is	 to	 investigate	 the	 variation	 in	 the	 concentration	 that	 causes	 50%	
growth	inhibition	(GI50)	in	the	National	Cancer	Institute	60	cancer	cell	line	panel	
(NCI-60)	for	any	compounds	that	the	cell	 lines	have	been	screened	for	multiple	




world	 leading	 research	setting	and	 thus	have	produced	a	 large	amount	of	data	














cuts	 to	 funding	and	personnel	 the	screening	 throughput	 is	still	at	around	3000	
samples	a	year	(Shoemaker,	2006).	
	
The	 NCI-60s	 inception	 was	 at	 a	 period	 of	 time	 in	 cancer	 research	 where	 the	
validity	and	reliability	of	work	was	being	questioned	due	to	an	inherent	problem	
with	misidentification	and	cross-contamination	of	cell	 lines	(Gillet	et	al.,	2013).	
The	 NCI-60	 ensured	 that	 rigorous	 authentication	 steps	 were	 taken	 and	 low	





With	 the	 recent	 escalation	 of	 a	 supposed	 “reproducibility	 crisis”	 (Wass	 et	 al.,	
2019)	there	is	perhaps	no	better	time	to	investigate	the	reliability	of	the	NCI-60	












NCI	 bulk	 data	 for	 download	 pages	
(https://wiki.nci.nih.gov/display/NCIDTPdata/NCI-
60+Growth+Inhibition+Data).	Of	the	52,585	NCI	codes	given	to	compounds	tested	
on	 the	 NCI-60	 cell	 line	 panel,	 42,794	were	 given	 to	 unnamed	 compounds	 and	
9,791	were	given	to	9,027	named	compounds.	262	named	compounds	received	
two	or	more	individual	codes.	Some	GI50	values	represent	minimum	or	maximum	





Data	 was	 carried	 out	 using	 perl	 version	 5.26.0,	 Microsoft	 Excel	 (2011)	 and	 R	
statistical	 packages	 version	 3.4.4.	 	 Perl	 modules	 Statistics:Descriptive	 and	
Statistics::R	 were	 used.	 Packages	 used	 in	 R	 were	 robustbase,	 dplyr,	 webr,	





that	was	 equal	 to	or	 less	 than	 the	minimum	dose	 concentration	or	 equal	 to	or	
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greater	 than	 the	maximum	dose	 concentration	was	 removed	 to	minimise	GI50	
“estimate”	values.	Any	compounds	with	only	one	experiment	were	 removed	as	
















>10,	 >100,	 and	 >1000)	 for	 combinations	 with	 varied	 number	 of	 experiments.	
Additionally,	 compound/cell	 line	 combinations	 were	 assigned	 to	 experimental	
groups:	 2	 experiments,	 3	 to	 5	 experiments,	 6	 to	 20	 experiments	 and	 over	 20	
experiments.	 These	 experimental	 groupings	 enabled	 comparison	 of	 GI50	 fold	
change	 statistics	 (mean,	 median,	 minimum,	 maximum,	 variance)	 for	











1012.1.	 The	 relationship	 between	 dose	 concentration	 range	 and	maximum	 fold	
change	 was	 investigated	 by	 using	 Spearman’s	 correlation	 coefficient	 as	 the	
distribution	of	maximum	GI50	fold	change	was	not	normal.	
	
Compound/cell	 line	 combinations	were	 assigned	 to	 groups	 based	 on	 the	 dose	
concentration	 range	 for	 that	 combinations:	maximum	concentration	 range	 less	
than	1.0	x	105,	maximum	concentration	range	1.0	x	105	to	1.0	x	109	exclusive	and	
maximum	concentration	range	1.0	x	109	and	above.	These	experimental	groupings	
enabled	 comparison	 of	 GI50	 fold	 change	 statistics	 (mean,	 median,	 minimum,	






All	 compounds	 that	 were	 classed	 as	 FDA-approved	 drugs	 by	 the	 NCI-60	 in	
CellMiner	Database	Version	2.2	and	where	 two	or	more	experiments	had	been	
performed	 were	 extracted	 from	 the	 complete	 dataset.	 This	 created	 an	 FDA-













change	 was	 then	 compared	 to	 the	 maximum	 GI50	 fold	 change	 for	 each	







compound,	 all	 cell	 lines	 and	 all	 experiments.	 Maximum	 fold	 changes	 were	
calculated	 for	 each	 compound/cell	 line	 combination	 with	 more	 than	 one	











The	 adjusted	 boxplot	 method	 (Hubert	 and	 Vandervieren,	 2008)	 was	 used	 to	
identify	outlier	 thresholds.	This	method	was	chosen	as	 the	data	 set	was	highly	
skewed.	It	is	also	more	robust	than	the	alternative	method	considered,	the	tukey	
outlier	method	(Tukey,	1977).	To	use	this	method	the	medcouple	(!"),	a	robust	
measure	 of	 skewness,	 had	 to	 be	 calculated	 (where	 #! = {	'", '#, …	 , '!	}	
represents	data	for	every	compound/cell	line	combination):	
	 	
!"('", …	 , '!) = -./




Where	-./% 	is	the	median	of	#!,	and	3	and	4	have	to	satisfy	'& ≤	-./% 	≤ 	 '$ ,	and	
'& ≠	'$ 	.	
Using	 the	!" 	the	 upper	 (U)	 and	 lower	 (L)	 thresholds	 could	 be	 determined.	 If	
!" ≥ 0	:	
9 = 	:" − 1.5	 × exp(−3.5!") × 	C:D	
E =	:' + 1.5	 × exp(4!") × 	C:D	
	
If	!" ≤ 0	:	
9 = 	:" − 1.5	 × exp(−4!") C:D	
E =	:' + 1.5	 × exp(3.5!") × 	C:D	
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If	!" = 0 	the	 adjusted	 boxplot	 method	 was	 not	 used	 but	 instead	 the	 Tukey	
method	was	used:	
9 = 	:" − 1.5C:D	
E =	:' + 1.5C:D	








Clustering	 analyses	 were	 performed	 using	 Euclidean	 clustering	 method.	 The	
optimum	number	of	clusters	was	calculated	using	affinity	propagation	method.	













and	highest	GI50	was	 calculated.	This	was	plot	 in	heatmaps	 to	determine	how	
experimental	 variability	 changed	 over	 time.	 To	 measure	 fold	 change	 between	
consecutive	experiments,	on	dates	where	multiple	experiments	occurred	for	a	cell	







All	 drug	 sensitivity	 data	 derived	 from	 NCI60	 testing	 are	 made	 available	 via	
Cellminer	 (https://wiki.nci.nih.gov/display/NCIDTPdata/NCI-
60+Growth+Inhibition+Data).	 In	 total,	 52,585	 compounds	 were	 tested	 in	 the	






in	 the	 NCI-60	 data.	 The	 highest	 GI∆	 observed	 was	 for	





mean	 illustrated	 the	 variation	 in	 GI∆	 however,	 the	 low	 median	 was	 perhaps	
misleading.	 The	 data	 was	 highly	 positively	 skewed	 for	 both	 the	 number	 of	
experiments	and	the	GI∆.	484,908	(81.6%)	of	all	CCCs	were	of	two	experiments,	
for	79,697	(13.4)	of	all	CCCs	there	was	no	fold	change	between	experiments	and	
for	362,135	(60.9%)	of	all	CCCs	 there	was	a	GI∆	of	 less	 than	2.	For	 this	reason	
experimental	groups	were	derived	with	two	things	in	mind:	
	




















4.1).	 The	mean	 and	median	maximum	GI∆	 for	 all	 CCCs	was	318,410	 (standard	
deviation	 (SD)	 =	 5.71	 x	 107)	 and	 1.6	 (interquartile	 range	 (IQR)	 =	 1.1-3.4),	
respectively.	 The	 low	 median	 fold	 change	 reflects	 the	 large	 number	 of	















CCCs >2 >5 >10 >100 >1000 >2 >5 >10 >100 >1000
All 11841 594450 232315 108247 59638 19089 8320 39.08 18.21 10.03 3.21 1.40
5+ 738 30212 25496 19448 14660 7205 3832 84.39 64.37 48.52 23.85 12.68
10+ 220 8517 8196 7461 6427 3948 2501 96.23 87.60 75.46 46.35 29.36
20+ 62 2950 2853 2764 2651 2075 1594 96.71 93.69 89.86 70.34 54.03
100+ 18 794 794 794 792 693 560 100.00 100.00 99.75 87.28 70.53











for	 a	 CCC	 increased,	 an	 increase	 in	 GIΔ	 was	 observed.	 To	 test	 this	 different	
experimental	 groups	 were	 considered:	 two	 experiments,	 three	 to	 five	
experiments,	five	to	20	experiments	and	greater	than	20	experiments.		
	




















Percentage	of	 CCCs	with	GI∆s	 above	 the	 indicated	 thresholds	 in	dependence	of	 the	number	of	
experiments.	B.	GI∆	in	dependence	on	the	number	of	experiments	per	CCC.	C.	Scatterplot	showing	




Taken	 together,	 maximum	 GI50	 fold	 changes	 increase	 with	 the	 number	 of	











tested	 on	 at	 multiple	 dose	 concentrations	 over	 the	 time	 course	 of	 the	 NCI-60	
screening,	 some	 over	more	 than	 others.	 As	with	 EXN,	 the	 concentration	 range	
covered	was	highly	positively	skewed.	547,256	(92%)	of	CCCs	were	tested	over	
the	 standard	 five-dose	 screen	 (albeit	with	 different	maximum	 concentrations).	














concentration	 range	 of	 1.0	 x	 109	 and	 above	 (Figure	 4.3A).	 In	 agreement,	 a	







Figure	 4.3	Variability	 increases	 as	 the	 dose	 concentration	 range	 tested	 on	 a	 compound	
increases.	A.	Distribution	of	GI50	fold	changes	in	dependence	of	the	concentration	ranges	in	which	
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range	 for	 fluorouracil	 (99.5%	 of	 experiments),	 doxorubicin	 (99.3%),	 and	




Cisplatin	had	been	 tested	more	 than	100	 times	 in	CCLs.	100	experiments	were	
performed,	in	which	100	GI50	values	for	each	cisplatin/cell	line	concentration	in	
the	 most	 commonly	 used	 concentration	 range	 (0.05-500µM)	 were	 randomly	
selected	 and	 the	 GI∆	 was	 calculated.	 A	 further	 random	 100	 selections	 were	




concentration	 ranges,	 than	 across	 100	 random	 samples	 from	 just	 one	 fixed	







may	 be	 speculated	 that	 FDA-approved	 drugs	 are	 more	 robust	 in	 their	 drug	



























of	 greater	 than	 1,000	 (Figure	 4.5A,	 Table	 4.1).	 For	 FDA	 approved	 CCCs	with	 a	




















when	 the	 FDA	 approved	 CCCs	 were	 grouped	 into	 combinations	 with	 two	
experiments,	 3	 to	 5	 experiments,	 6	 to	 20	 experiments,	 and	 greater	 than	 20	
experiments.	 For	 CCCs	with	 two	 experiments	 the	mean	 and	median	 GI∆	were	
433.4	(SD	=	16,619)	and	1.4	(IQR	=	1.1-2.3),	for	CCCs	with	3	to	5	experiments	319.8	
(SD	=	2,337)	and	4.2	(IQR	=	1.7-23.7),	for	CCCs	with	6	to	20	experiments	99,189	








Number of  
CCCs
>2 >5 >10 >100 >1000
All Data 9971 5752 4213 3547 2065 1361
5 and Over 3745 3533 3206 2868 1849 1295
10 and Over 2718 2594 2470 2312 1633 1225
20 and Over 2187 2089 2008 1911 1461 1168




CCCs.	 A.	 Percentage	 of	 FDA	 approved	 CCCs	 with	 GI∆s	 above	 the	 indicated	 thresholds	 in	
dependence	of	the	number	of	experiments.	B.	GI∆	in	dependence	on	the	number	of	experiments	




















and	 the	GI∆	 (Spearman's	 correlation	coefficient	=	0.62,	p	<	2.2	x	10-16)	 (Figure	





For	analysis	of	outliers	 there	were	 two	main	aims.	The	 first	was	 to	 investigate	
whether	 there	 was	 any	 variability	 caused	 by	 specific	 CCLs	 or	 compounds.	 To	





GI50s	 and	 repeat	 previous	 analyses	 to	 see	 if	 the	 level	 of	 variability	 was	 still	
present,	or	was	caused	by	individual	outliers.	Using	these	two	methods	made	it	
possible	to	investigate	whether	individual	compounds	or	CCLs	were	more	likely	













how	many,	 if	 any,	 compounds	 GI∆s	 could	 be	 considered	 outliers.	 For	 all	 data,	
outlier	percentage	(percentage	of	total	compound	GI∆s	for	a	CCL	considered	an	
outlier)	ranged	from	4.45%	(115	outliers	 from	2587	compounds,	breast	cancer	
CCL	HS	578T)	 to	 6.86%	 (189	 outliers	 from	2754	 compounds,	 lung	 cancer	 CCL	



















































































Cisplatin GI50 Outliers for NCI 60 Cancer Cell Lines
(Percentage of Cell Line Total GI50 Measurements)
Table	4.3	–	Compound	Outlier	
Frequency	 	 	 	 	
	 	 	 	 	 	 	 	




Outlier	 Minimum	 Min	Compound	 Maximum	 Max	Compound	
All	 4030	 1273	 31.59	 1	 453	Compounds	 60	 12	Compounds	
5_+	 562	 149	 26.51	 1	 44	Compounds	 58	 Vinblastine	
10_+	 205	 37	 18.05	 1	 9	Compounds	 49	 Maytansine	
20_+	 61	 20	 32.79	 1	 5	Compounds	 41	 2	Compounds	
100_+	 18	 14	 77.78	 1	 Bleomycin	 11	 Vinblastine	
FDA	
Approved	 178	 52	 29.21	 1	 11	Compounds	 60	 Vinblastine	
Clinical	Trial	 69	 29	 42.03	 1	 11	Compounds	 47	 Dolastatin10	
Figure	4.7	Percentage	of	GI∆	outliers	for	each	NCI-60	cell	line	
Chapter	4	 117	
As	 with	 previous	 analyses,	 the	 alternative	 experimental	 groups	 (all	 data,	 5+	
experiments,	 10+,	 20+,	 100+)	 were	 tested	 to	 determine	 the	 impact	 of	 large	










was	 similar	 to	 the	 20+	 and	 FDA	 approved	 groups	 (32.8%	 and	 29.2%).	 In	 the	
remaining	two	groups,	100+	(77.8%)	and	clinical	trial	(42.03%),	the	number	of	
compounds	 as	 a	 percentage	 increased.	 Vinblastine	 and	 Maytansine	 were	
repeatedly	among	the	outlier	compounds	most	frequently	present	if	not	the	most	
frequent	for	all	groups	they	were	present	in,	and	particularly	for	the	three	groups	


















lowest	 outlier	 percentage	was	 1.67%	 (one	 out	 of	 60	 CCLs)	 for	 32	 compounds,	
while	the	highest	was	40%	(two	out	of	five	CCLs	for	compound	1h-pyrazolo[3,4-
d]pyrimidine,	 4-amino-1-(p-chlorobenzyl),	 NSC#	 63629).	 Every	 CCL	 was	 an	
outlier	 for	 at	 least	 73	 compounds	 (CCL	 MDA-N)	 and	 for	 as	 many	 as	 249	





the	most	 compounds	was	 different	 for	 every	 group.	 For	 the	 complete	 data	 set	
there	 was	 a	 negative	 correlation	 between	 EXN	 and	 CCL	 outlier	 for	 individual	
compounds	(correlation	=	-0.68,	p<2.2	x	10-16).	Again	this	is	likely	due	to	not	many	
GI∆	 from	high	EXNs	 being	 classed	 as	 outliers.	No	GI∆	 from	 an	EXN	 above	 127	
generated	a	CCL	outlier	for	a	compound,	which	is	maybe	not	surprising	as	95	of	











GI50	outlier	number	 is	high	 in	 the	NCI60	data.	Of	 the	598,243	 individual	GI50	
values	considered	for	outlier	analysis,	5.7%	(34,216)	were	outliers.	For	CCLs	with	
at	least	5	experiments,	43.7%	(13,208/30,212)	CCCs	had	at	least	one	GI50	outlier.	
The	 highest	 percentage	 of	 outliers	 was	 for	 50%	 (7/14)	 of	 experiments	 for	
compound	maytansine	on	prostate	CCL	DU-145	(Figure	4.8A),	and	 the	greatest	
number	of	outliers	was	291	(of	1731	experiments,	16.8%)	for	fluorouracil	on	lung	
CCL	 HOP-62	 (Figure	 4.8B).	 The	 lowest	 percentage	 of	 outliers	 of	 those	
combinations	 with	 outliers	 present	 was	 0.79%	 (1/128)	 of	 all	 experiments	 for	






number	 of	 outliers	 was	 doxorubicin	 with	 5504	 (4.2%	 of	 total	 129,815	
experiments)	over	59	of	the	60	cell	lines,	which	was	also	the	highest	among	the	
compounds	 with	 outliers.	 The	 compound	 with	 the	 highest	 number	 of	 outliers	
Chapter	4	 120	
relative	 to	 the	 total	 experiments	 carried	 out	 was	 15-desacetylsergeolide	 with	
20.6%	 (53/257	 experiments).	 A	 positive	 correlation	 was	 observed	 between	
maximum	 experiment	 number	 for	 a	 compound	 and	 the	 number	 of	 outliers	
(Spearman	correlation	coefficient	=	0.52,	p	<	2.2	x	10-16).	
	
All	 60	 cell	 lines	 had	 at	 least	 84	 outliers	 (breast	 CCL	 BT-549)	 and	 the	 greatest	
number	of	outliers	was	1062	for	renal	CCL	SN12C.	Both	also	had	the	least	and	most	
number	of	outliers	compared	to	total	experiments,	0.44%	(84/18,808)	for	BT-549	





Despite	 the	 large	 number	 observed,	 outliers	 were	 not	 responsible	 for	 the	
variability	we	see	in	the	data.	Removal	of	outlier	GI50	values	from	the	dataset	does	


























































was	 seen,	 the	 maximum	 fold	 change	 for	 CCCs	 with	 outlier	 data	 removed	 was	
drastically	altered	in	many	cases.	A	decrease	in	GI∆	was	seen	in	13,208	(43.7%)	





































to	 2.56E+10	 (vinblastine,	 SNB-75)	 while	 a	 maximum	 fold	 change	 between	
consecutive	experiments	of	at	least	1.42E+03	was	seen	in	14	of	the	remaining	16	
compounds.	 Maximum	 fold	 change	 was	 calculated	 for	 each	 CCL	 for	 each	
compound	 using	 the	 highest	 and	 lowest	 GI50	 value	 at	 any	 point	 in	 the	 CCLs	
experimental	time	line,	resulting	in	maximum	fold	change	for	a	compound	ranging	











Actinomycin	D	 1989-07	 2009-12	 245	 132	
Bleomycin	 1989-07	 2008-08	 229	 131	
Carmustine	 1989-07	 2008-08	 109	 128	
Chlorambucil	 1989-07	 2006-11	 208	 130	
Cisplatin	 1989-07	 2010-04	 249	 139	
Cytarabine	 1989-07	 1997-06	 95	 130	
Daunorubicin	 1989-07	 1997-06	 95	 126	
Doxorubicin	 1993-08	 2016-07	 275	 2348	
Floxuridine	 1989-07	 1997-06	 95	 124	
Fluorouracil	 1993-08	 2007-02	 162	 1886	
M-AMSA	 1989-07	 2006-11	 208	 132	
6-Mercaptopurine(1)	 1989-07	 2004-06	 179	 130	
6-Mercaptopurine(2)	 1989-07	 1997-06	 95	 127	
Methotrexate	 1989-07	 2006-11	 208	 134	
Mitomycin	 1989-07	 2004-06	 179	 129	
Thiotepa	 1989-07	 2008-08	 229	 136	
Triethylenemelamine	 1989-07	 1997-06	 95	 128	





allowed	us	 to	 determine	which	 compounds	 and	CCLs	were	most	 variable	 over	
their	experimental	time	frame.	Figure	4.9	displays	the	results	from	this	analysis	


























































































































































































































































































































































































































































































































































































































































































From	the	cluster	analysis	 it	 is	apparent	that	there	were	drugs	that	had	a	 lower	















similar.	When	considering	 the	data	 for	 fold	 changes	of	 greater	 than	2	between	
consecutive	experiments	(Figure	4.9A),	Actinomycin	d	and	vinblastine	clustered	
together	in	one	cluster	and	were	clearly	the	two	drugs	with	the	highest	number	of	
fold	 changes	 greater	 than	 2	 between	 experiments.	 However,	 they	 both	 have	
different	mechanisms	of	action.	Actinomycin	d	inhibits	transcription	by	binding	to	
DNA,	while	vinblastine	is	microtubule	disrupting.	Furthermore,	drugs	with	similar	
mechanisms	 of	 action	 did	 not	 cluster	 together.	 Topoisomerase	 II	 inhibitors	











Taking	maximum	 fold	 change	 and	 the	 number	 of	 ‘high’	 fold	 changes	 between	
consecutive	 experiments	 into	 consideration,	 vinblastine,	 actinomycin	 d	 and	
floxuridine	 appear	 to	 contain	 the	 most	 GI50	 variation,	 whereas	 doxorubicin,	
chlorambucil	 and	 triethylenemelamine	 the	 least.	The	data	 certainly	 shows	 that	
maximum	fold	change	can	not	be	considered	the	only	indicator	of	GI50	variability	
as	Doxorubicin,	with	less	variation	when	considering	only	‘high’	fold	changes	(±2	
and	 ±5)	 between	 experiments,	 giving	 the	 third	 highest	 maximum	 fold	 change	
(1.00E+08,	 IGROV1)	 and	 third	 highest	 fold	 change	 between	 two	 consecutive	
experiments	 (2.18E+06).	 This	 can	 be	 seen	 in	 the	 timeline	 plot	 for	 doxorubicin	
(Figure	4.10A),	a	large	spike	in	the	data	is	likely	an	outlier	responsible	for	these	
high	fold	change	values.		Similarly,	a	large	number	of	instances	where	there	was	
no	 change	 in	 GI50	 between	 consecutive	 experiments	 cannot	 be	 considered	 a	
reliable	 indicator	 of	 GI50	 variability	 when	 used	 alone.	 In	 multiple	 CCLs	 for	
vinblastine	 for	 example	 (Figure	 4.10B),	 there	was	 no	 change	 in	 GI50	 between	
multiple	consecutive	experiments.	In	one	CCL,	no	change	in	GI50	was	observed	for	
24.24%	consecutive	experiments,	while	42%	fold	changes	were	of	at	least	±5.	One	
very	apparent	observation	 that	can	be	made	 is	 that	all	CCLs	 for	all	 compounds	
Chapter	4	 129	














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the	 start	 point	 and	 endpoint	 were	 variable	 between	 CCLs.	 For	 every	 single	
compound	at	least	one	CCL	that	had	identical	or	close	to	identical	start	and	end	
points	(minimum	fold	varied	from	no	change	in	GI50	(31	CCLs	over	8	compounds)	














changes	predominantly	 in	one	direction	 for	 the	majority	of	CCLs.	Chlorambucil	
GI50	 fold	 changes	were	much	 lower	 and	 start/end	 fold	 changes	were	 low	 and	
Chapter	4	 132	










The	 distribution	 of	 the	 individual	 GI50	 values	 for	 three	 of	 the	 CCCs	
(floxuridine/SK-OV-3,	methotrexate/BT-549,	6-mercaptopurine/BT-549)	did	not	
indicate	 a	 GI50	 shift	 over	 time	 (Figure	 4.11A-C).	 For	 the	 other	 three	 CCCs	
(bleomycin/K-562,	 vinblastine/T-47D,	 M-AMSA/MDA-MB-435)	 a	 drift	 in	
















maximum	GI50	 for	 that	 combination.	 Compound/cell	 line	 combinations	 are	A.	 floxuridine	 and	
ovarian	 cancer	 cell	 line	 SK-OV-3,	 B.	 methotrexate	 and	 breast	 cancer	 cell	 line	 BT-549,	 C.	 6-	
mercaptopurine	and	breast	cancer	cell	line	BT-549,	D.	bleomycin	and	leukaemia	cell	line	K-562,	E.	
vinblastine	and	breast	cancer	cell	line	T-47D	and	F.	M-AMSA	and	melanoma	cell	line	MDA-MB-435.	


















Figure 4 Experimental time lines for individual compound/cell line combinations. The 6 experimental timelines
for compound/cell line combinations (amongst compounds for which at least one cell line has 100 experiments
performed on) with a fold change between the mean GI50 at the first experimental date and final experimental date that
is greater than 50% the value of the maximum GI50 for that combination. Compound/cell line combinations are A.
floxuridine and ovarian cancer cell line SK-OV-3, B. methotrexate and breast cancer cell line BT-549, C. 6-
mercaptopurine and breast cancer cell line BT-549, D. bleomycin and leukaemia cell line K-562, E. vinblastine and
breast c ncer cell line T-47D and F. M-AMSA and elanoma ll line MDA-MB-435. Plot line represents me GI50











For	 three	 compounds,	 no	 outliers	 were	 present	 in	 more	 than	 50%	 of	 CCLs:	
methotrexate	 (42/60),	 cytarabine	 (39/60)	 and	 floxuridine	 (31/60).	 The	
remaining	CCLs	did	contain	high	levels	of	outliers	for	methotrexate,	nine	of	the	



































































Carmustine GI50 Outliers for NCI 60 Cancer Cell Lines
(Percentage of Cell Line Total GI50 Measurements)
Figure	4.12	Percentage	of	carmustine	GI50	values	that	are	outliers	for	all	cell	lines	
Chapter	4	 135	










compound	are	displayed	 in	 figure	4.13.	 It	 is	clear	 that	 the	compounds	with	 the	
largest	 amount	 of	 outliers	 for	 CCLs	 are	 carmustine,	 actinomycin	 d	 and	











The	 drugs	 clustered	 into	 5	 clusters.	 Actinomycin	 d	 (cluster	 3)	 and	
daunorubicin	(cluster	2)	clustered	individually	with	a	large	number	of	
outliers	in	few	CCLs.	Carmustine	displayed	a	large	number	of	outliers	
for	 the	majority	 of	 CCLs	 and	 also	 clustered	 individually	 (cluster	 1).	
Cluster	4	(9	drugs)	displayed	relatively	low	amounts	of	GI50	outliers	





























































































































medium	 number	 of	 GI50	 outliers	 across	 all	 CCLs	 (Figure	 4.13).	
Interestingly,	3	of	the	5	DNA	synthesis	inhibitors	clustered	in	cluster	4	
while	4	of	the	5	alkylating	agents	clustered	together	in	cluster	5.	With	





were	 some	 examples	 of	 clustering	 by	 cancer	 site,	 leukaemia	 CCLs	
clustered	closely	together	and	displayed	less	outliers	in	carmustine,	a	
drug	that	many	GI50	outliers	were	recorded	for	other	CCLs.	There	was	
evidence	 of	 clustering	 by	 other	 cancer	 sites.	 Colorectal,	 melanoma,	





Although	 outlier	 number	 is	 no	 doubt	 an	 indicator	 of	 some	 sort	 of	
variability	with	 regards	 to	GI50	measurements,	 it	 is	not	possible	 to	
determine	 whether	 or	 not	 a	 CCL	 or	 drug	 displays	 more	 or	 less	
Chapter	4	 138	











EXN	 of	 two)	 (Table	 4.5).	 The	 number	 of	 CCCs	 greatly	 increases	 for	 these	 two	
compounds	as	well.	The	number	of	combinations	was	15,998	for	doxorubicin	and	
9525	 for	 fluorouracil	while	 for	 the	 other	 compounds	 CCC	 number	 varies	 from	
1639	to	2036.	The	number	of	dates	experiments	were	carried	out	on	also	varied;	




















4.14A)	 and	 triethylenemelamine	 (Figure	 4.14B).	 The	 large	 changes	 in	 GI50	 as	
highlighted	in	figure	4.15	are	undoubtedly	responsible	for	the	large	GI∆,	but	the	
change	 in	 GI50	 is	 in	 opposite	 directions	 for	 floxuridine	 (4.15A)	 and	
triethylenemelamine	(4.15B).	
	
Compound Minimum Maximum Mean Number of 
CCCs
Number Dates
Methotrexate 2 6 3.22 1814 40
6-Mercaptopurine(2) 2 5 3.3 1821 39
6-Mercaptopurine(1) 2 5 3.29 1738 37
Actinomycin D 2 5 3.27 1875 40
Chlorambucil 2 5 3.34 1798 38
Thiotepa 2 5 3.17 1996 45
Trethylenemelamine 2 5 3.31 1790 38
Fluorouracil 2 32 10.69 9525 163
Mitomycin 2 5 3.29 1822 39
Floxuridine 2 5 3.33 1700 34
Vinblastine 2 6 3.38 1639 34
Cytarabine 2 5 3.26 1711 37
Daunorubicin 2 5 3.32 1757 37
Cisplatin 2 5 3.16 2036 44
Doxorubicin 2 35 8.11 15998 276
Bleomycin 2 5 3.24 1866 40
MAMSA 2 7 3.41 1791 38
Carmustine 2 5 3.26 1821 38













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The	 most	 striking	 result	 from	 this	 analysis	 is	 the	 variability	 of	 GI50	 for	 a	






fold	 for	 a	 resistant	 CCL	 to	 be	 established	 (McDermott	 et	 al.,	 2014).	 Barr	 et	 al.	
(2013)	 described	 four	 non-small	 cell	 lung	 cancer	 (NSCLC)	 CCLs	 as	 cisplatin	
resistant	after	continuous	exposure	 to	cisplatin	generated	 IC50	 fold	changes	of	
between	4	and	15	compared	to	parental	CCL.	Even	a	fold	increase	in	IC50	of	2500	











these	GI∆	will	be	GI∆C)	 in	a	compounds	experimental	 timeline	(experiments	 in	
order	of	date	performed).	Mcdermott	et	al.	(2014)	defined	a	CCL	to	be	clinically	
relevant	 resistant	 if	 2	 to	 5	 fold	 different	 from	 parental	 cell.	 Although	 not	









CCLs	 were	 not	 prone	 to	 higher	 levels	 of	 variability	 between	 consecutive	
experiments.	Drugs	with	 the	same	mechanism	of	action	did	not	display	similar	
levels	 of	 variability	 between	 consecutive	 experiments	 and	 did	 not	 cluster	
together.		
	
The	 GI∆	 increased	 with	 both	 the	 number	 of	 experiments	 and	 the	 dose	
concentration	 range	 covered.	 This	would	 perhaps	 be	 expected	 as	 the	multiple	
testing	gives	rise	to	a	higher	probability	of	outliers,	and	the	similarly	with	the	dose	
concentration	 range,	 the	 higher	 the	 range	 the	 higher	 the	 probability	 that	 two	










are	 certainly	 not	 conducive	 to	 either.	 The	 NCI-60	 provides	 data	 that,	 if	 used	
correctly,	 grants	 insight	 into	 many	 aspects	 of	 cancer	 biology	 and	 drug	
development,	 in	 chapter	 2	 it	 was	 illustrated	 how	 the	 data	 could	 be	 used	 to	




been	 questioned	 in	 recent	 years.	 Haibe-Kaines	 et	 al.	 (2013)	 described	 poor	
correlation	of	drug	response	between	the	Cancer	Cell	Line	Encyclopedia	(CCLE)	
and	 the	 Genomics	 of	 Drug	 Sensitivity	 in	 Cancer	 (GDSC)	 pharmacogenomics	














the	 CCLs	 used	 in	 screening	 now	 have	 a	 large	 passage	 number.	 It	 is	 well	
documented	 that	 passage	 number	 can	 affect	 a	 CCLs	 characteristics	 over	 time	
(Esquenet	et	al.,	1997;	Wenger	et	al.,	2004).	Ben-David	et	al.	(2018)	reported	that	
















latest	 experiment	 compared	 to	 the	 GI50	 at	 the	 beginning	 of	 the	 timeline.	 GI∆	
ranges	from	1.1	to	84	for	these	CCLs.	Does	this	mass	rise	or	fall	in	GI50	over	this	
Chapter	4	 146	


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Lack	 of	 proper	 training	 or	 skills	 to	 carry	 out	 experimental	 protocols	 has	 been	
suggested	as	one	of	the	possible	contributors	to	the	reproducibility	crisis	(Garijo	
et	 al.,	 2013).	 Even	 though	 the	 actual	 screening	of	 CCLs	 is	 high-throughput	 and	
performed	by	machines,	there	will	always	be	a	human	element	to	the	process.	It	is	








4.9B	 shows	 this	 phenomenon	 for	 triethylenemelamine.	 For	 August	 1993	 GI∆	
between	experiments	for	a	CCL	ranged	from	1.02	to	19.14	(median	=	2.2,	mean	
=3.2),	 then	 for	October	GI∆	 suddenly	 increased	and	 ranged	 from	1.1	 to	2269.9	




unlikely	 to	 be	 coincidental	 outliers	 for	 all	 compounds,	 so	must	 be	 error	 in	 the	









last	 experiments	 on	 the	 timeline,	 and	 produced	 many	 high	 GI∆s	 between	
experiments	in	all	CCLs.	Chlorambucil	on	the	other	hand	produced	relatively	low	















However,	measuring	 the	 level	 of	 variability	 for	 comparison	 is	 not	 so	 easy.	 For	
example	it	is	not	easy	to	determine	whether	individual	CCLs,	compounds	or	CCCs	





Firstly	what	 is	 considered	 a	 “high”	 fold	 change?	This	 is	 largely	 subjective.	And	
using	 thresholds	 for	 “high”	 does	 not	 describe	 to	 what	 extent	 the	 fold	 change	
between	experiments	is	actually	high.	For	some	CCCs	the	fold	change	may	be	very	














variability	 (Alley	et	 al.,	 1988;	 Shoemaker	et	 al.,	 1988),	 a	 significant	 part	 of	 the	
observed	 data	 variation	 is	 likely	 due	 to	 the	 inherent	 complexity	 of	 biological	
systems.	It	is	not	entirely	clear	what	these	findings	mean	and	to	which	extent	the	
further	 understanding	 of	 the	 parameters	 influencing	 experimental	 results	 in	
biological	 systems	 can	 be	 used	 in	 the	 future	 to	 increase	 data	 replicability.	
Chapter	4	 151	
Experiment	 heterogenisation,	 the	 testing	 of	 a	 hypothesis	 in	 many	 different	
(experimental)	systems	and	datasets	and	different	laboratories	(Karp	et	al.,	2014;	
Ding	et	al.,	2017;	Kafkafi	et	al.,	2017),	has	been	suggested	to	provide	more	robust	
and	meaningful	data.	This	 interpretation	 is	also	 in	 line	with	the	NCI60	strategy	
that	 emphasises	 that	 follow-up	 testing,	 including	 animal	 testing,	 is	 needed	 to	
identify	drug	 leads	 (Shoemaker,	2006).	However,	 further	 research	will	need	 to	

























the	 world	 of	 cancer	 drug	 discovery	 in	 terms	 of	 new	 drugs	 discovered,	 but	
definitely	in	terms	of	large	changes	in	the	philosophy	and	practice	of	cancer	drug	
research.	 That	 is	 not	 to	 say	 that	 it	 hasn’t	 had	 success	with	 drug	 development	
(Holbeck	 et	 al.,	 2004;	 Bai	 et	 al.,	 1991;	 Beck	 et	 al.,	 2015),	 but	 its	 greatest	
contribution	has	been	to	bring	forward	the	concept	of	representing	the	diversity	
of	cancers	 in	one	panel	 in	a	cell	 line	screen.	This	once	novel	 idea	has	spawned	
further	 large-scale	 pharmacogenomics	 cell	 line	 screens	 the	 Cancer	 Cell	 Line	
Encyclopedia	(CCLE)	and	the	Genomics	of	Drug	Sensitivity	in	Cancer	(GDSC)	which	























oxaliplatin	 using	 the	 Cmax	 which	 is	 the	 therapeutically	 achievable	 dose	 in	 a	
patient	(the	dose	before	potentially	lethal	side	effects)(Endrenyi	et	al.,	1991).			
	




et	 al.,	 2009).	 Oxaliplatin	 is	 often	 used	 as	 an	 alternate	 therapy	 for	 cancers	 that	
possess	intrinsic	resistance	or	acquired	resistance	to	cisplatin	or	carboplatin	or	
Discussion	 154	
cross	 resistance	 due	 to	 adapted	 resistance	 to	 one	 or	 the	 other	 (Comella	 et	 al.,	








A	 consideration	 regarding	 the	 determination	 of	 therapeutically	 achievable	






determined.	Secondly,	 the	 therapeutically	achievable	dose	 for	a	patient	 is	often	
calculated	differently	 for	different	drugs.	For	example,	 for	some	drugs	 the	area	
under	the	curve	(AUC)	is	used	to	determine	the	dose	for	a	patient.	This	is	the	case	
for	one	of	the	drugs	in	this	analysis,	carboplatin	(van	Warmerdam	et	al.,	1995).	
This	must	be	considered	and	 in	 further	work	a	 therapeutically	achievable	dose	
should	 be	 calculated	 using	 the	 correct	 pharmacokinetic	 parameter	 where	
possible.	Using	pharmacokinetic	parameters	to	determine	cell	line	sensitivity	has	
shown	 that	 there	 is	 a	 difference	 in	 sensitivity	 profiles	 in	 three	 platinum	drugs	
compared	to	when	determining	drug	sensitivity	for	cell	lines	with	regards	to	each	
Discussion	 155	
other.	 This	 probably	 reflects	 that	 the	 clinical	 activity	 of	 a	 drug	 is	 not	 only	
determined	by	its	mechanism	of	action	but	also	by	its	pharmacokinetics	(Wagstaff	
et	 al.,	 1989;	 Levi	 et	 al.,	 2000;	 O’Dwyer	 et	 al.,	 2000;	 Burger	 et	 al.,	 2011).	 This	









difficult.	 Biomarkers	 are	 easier	 to	 identify	 for	 intrinsic	 resistance	 as	 initial	
response	to	treatment	is	easy	to	measure	–	it	either	works	or	it	doesn’t.	But	the	
heterogeneity	 of	 cancer	 means	 that	 it	 is	 likely	 that	 the	 processes	 resulting	 in	








In	a	panel	of	10	neuroblastoma	cell	 lines	adapted	 to	 the	drug	YM-155,	wet	 lab	
collaborators	identified	a	number	of	resistance	mechanisms	present	that	were	not	
Discussion	 156	
in	 the	 parental	 cell	 line.	 The	 levels	 of	 two	 genes	 were	 of	 particular	 interest,	
multidrug	 resistance	 protein	 ABCB1	 and	 solute	 carrier	 SLC35F2.	 ABCB1	 levels	







Positive	 correlation	 between	 ABCB1	 and	 YM-155	 sensitivity,	 and	 negative	
correlation	between	SLC35F2	and	YM-155	was	observed	in	both	CTRP	and	GDSC	
data.	Furthermore,	they	both	were	the	highest	correlated	genes	in	both	datasets.	





considering	 only	 neuroblastoma	 cell	 lines.	 However,	 importantly	 although	 the	
association	between	YM155	sensitivity	and	ABCB1/SLC35F2	 levels	 in	the	GDSC	







treatment	 that	 may	 not	 necessarily	 predict	 therapy	 outcome	 in	 therapy	 naive	
cancer	cells.	A	realistic	way	to	do	this	is	by	using	pre	clinical	models	of	acquired	
drug	resistance,	a	method	of	which	we	have	shown	in	this	study.	The	emergence	
of	 ABCB1	 and	 SLC35F2	 as	 biomarker	 candidates	 for	 YM155	 resistance	 in	 our	
research	highlights	the	potential	of	drug	adapted	cancer	cell	line	models	to	identify	
biomarkers	 that	 can	 be	 used	 in	 the	 design	 of	 individualized	 therapies.	 These	
conclusions	could	not	have	been	made	if	it	wasn’t	for	the	computational	analysis	
highlighting	the	 importance	of	not	only	the	use	of	pharmacogenomic	data	 from	







It	 was	 established	 at	 a	 time	 when	 cell	 line	 misidentification	 and	 cross-















Moreover,	 variability	 increased	 when	 the	 number	 of	 experiments	 or	 dose	




The	 variability	 observed	 for	 FDA	 approved	 anti-cancer	 drugs	 is	 of	 potential	
relevance,	given	that	cytotoxic	anti-cancer	drugs	are	typically	used	at	maximum	
tolerated	doses	 that	 cannot	 be	 further	 increased	without	unacceptable	 toxicity	
(Eisenhauer	et	al.,	2000;	Sachs	et	al.,	2000;	Mansino	et	al.,	2019).	Moreover,	the	
maximum	 effects	 of	 targeted	 drugs,	 e.g.	 antibodies	 or	 kinase	 inhibitors,	 that	















in	 part	 the	 underlying	 complex	 biology.	 This	 work	 raises	 awareness	 of	 the	
inherent	variability	of	experimental	results,	and	will	hopefully	allow	us	to	develop	



























significant	 level	 of	 intratumoural	 heterogeneity	 present	 in	 the	 NCI-60	 CCL	
collection.	This	may	explain	some	of	the	GI50	variability	observed	in	this	analysis.	











Drug	 solubility	 may	 be	 an	 important	 factor	 in	 drug	 sensitivity	 measurement	
variability.	 Poor	 water	 solubility	 is	 an	 inherent	 property	 of	 many	 anti-cancer	
drugs.	Hydrophobicity	and	lipophilicity	are	required	for	anti-cancer	drugs	to	cross	
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cell	 membranes	 (Lipinski,	 2000)	 and	 a	 low	 polar	 surface	 area	 increases	
permeability	of	the	drug,	but	as	the	polar	surface	area	decreases	so	too	does	the	
water	solubility	(Veber	et	al.,	2002).	Balance	between	the	two	is	difficult.	If	an	anti-














HSP90	 inhibitor	 reduced	 growth	 rate	 of	 a	mouse	melanoma	 in	 a	 time-of-day–
specific	manner,	but	efficacy	was	 impaired	in	clock-deficient	tumors	(Lee	et	al.,	
2021).	Another	example	 involves	one	of	 the	platinum	drugs	used	 in	 chapter	2,	
oxaliplatin.	 Oxaliplatin	 development	 was	 halted	 after	 excessive	 toxicities	 in	 a	
phase	I	clinical	trial.	Later	though	it	was	found	that	if	the	drug	was	delivered	at	
certain	times	in	the	day,	the	toxicities	were	avoided	and	eventually	passed	phase	
II	 (Levi	 et	 al.,	 1992)	 and	 III	 (Levi	 et	 al.,	 1997)	 trials	 using	 chronomodulated	
delivery.	It	 is	unknown	whether	drug	screens	in	the	pharmacogenomic	cell	 line	
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Pharmacogenomics	 screening	 of	 cancer	 cell	 line	 panels	 produces	 valuable	
drug	sensitivity	and	genomic	data.	This	data	can	be	used	to	validate	experimental	
work	as	was	shown	in	chapter	3	when	computational	analysis	of	data	from	two	of	




likely	 biomarkers	 of	 acquired	 resistance	 rather	 than	 intrinsic	 resistance.	 Data	
from	 the	 NCI-60	 was	 used	 to	 develop	 a	 novel	 method	 to	 determine	 cell	 line	
sensitivity	that	could	perhaps	be	of	use	when	translating	preclinical	 findings	to	
the	clinical	setting.	Using	clinically	relevant	thresholds	for	sensitivity	of	platinum	
compounds,	 differences	were	 seen	 between	 compounds	 that	weren’t	 apparent	
when	only	considering	cell	 line	sensitivity	with	relation	to	other	cell	 lines.	This	
additional	role	of	pharmacokinetics,	not	just	the	mechanism	of	action,	needs	to	be	
taken	 into	 account	 during	 the	 translation	 of	 preclinical	 findings.	 Finally,	 data	




in	 experimental	 compounds.	 Even	widely	 used	 FDA	 approved	 drugs	 displayed	
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high	 levels	 of	 variability.	 Perhaps	 variability	 is	 an	 intrinsic	 trait	 of	 biological	






variables	mentioned	 in	 the	 discussion.	 The	 clonal	 heterogeneity	 of	 cancer	 cell	
lines,	 drug	 solubility	 and	 cell	 line	 circadian	 rhythm.	 Another	 variable	 not	
mentioned	 is	 the	 doubling	 time	 of	 cell	 lines.	 Comparing	 the	 sensitivity	 of	DNA	
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Table S1. YM155 concentrations (nM) that reduce the viability of UKF-NB-3 or 
YM155-adapted UKF-NB-3 sub-lines by 50% (IC50) or 90% (IC90) as indicated by 
MTT assay after 120h of incubation and doubling times of the cells. 
 
 IC50  IC90 Doubling times 
(h) 
UKF-NB-3 0.55 ± 0.06 1.01 ± 0.24 30.8 ± 0.8 
UKF-NB-3rYM15520nMI 36.2 ± 2.0 (66)1 94.8 ± 0.7 (94)2 41.5 ± 5.2 
UKF-NB-3rYM15520nMII 23.6 ± 2.2 (43) 39.9 ± 0.9 (40) 39.2 ± 4.8 
UKF-NB-3rYM15520nMIII 31.8 ± 2.3 (58) 49.1 ± 0.2 (49) 32.3 ± 1.1 
UKF-NB-3rYM15520nMIV 21.0 ± 0.6 (38) 29.8 ± 4.8 (30) 32.2 ± 2.0 
UKF-NB-3rYM15520nMV 25.1 ± 0.1 (45) 39.5 ± 0.7 (39) 35.3 ± 2.8 
UKF-NB-3rYM15520nMVI 41.9 ± 5.3 (76) 136 ± 7 (135) 36.3 ± 2.2 
UKF-NB-3rYM15520nMVII 36.5 ± 5.5 (66) 96.2 ± 23.9 (95) 46.1 ± 2.1 
UKF-NB-3rYM15520nMVIII 34.5 ± 0.6 (63) 84.7 ± 27.3 (84) 47.0 ± 2.5 
UKF-NB-3rYM15520nMIX 27.2 ± 0.5 (49) 44.8 ± 2.9 (44) 33.3 ± 0.2 
UKF-NB-3rYM15520nMX 26.9 ± 0.5 (49) 45.2 ± 4.7 (45) 41.9 ± 2.2 
 
1 fold resistance (IC50 YM155-adapted sub-line/ IC50 UKF-NB-3) 
2 fold resistance (IC90 YM155-adapted sub-line/ IC90 UKF-NB-3) 
 
Table S2. Drug concentrations that reduce the viability of UKF-NB-3 or YM155-adapted UKF-NB-3 sub-lines by 50% (IC50) as 
indicated by MTT assay after 120h of incubation. 
 
 Nutlin-3 Vincristine Cisplatin Gemcitabine Topotecan 
 IC50 (µM) IC50 (ng/mL) IC50 (ng/mL) IC50 (ng/mL) IC50 (ng/mL) 
UKF-NB-3 1.05 ± 0.25 1.75 ± 0.55 169 ± 29 0.30 ± 0.03 1.29 ± 0.52 
UKF-NB-3rYM15520nMI 0.57 ± 0.07 (0.5)1 45.5 ± 11.1 (26) 157 ± 54 (0.9) 0.64 ± 0.02 (2.1) 1.37 ± 0.53 (1.1) 
UKF-NB-3rYM15520nMII 1.31 ± 0.03 (1.2) 27.0 ± 12.6 (15) 183 ± 51 (1.1) 0.50 ± 0.04 (1.7) 1.25 ± 0.53 (1.0) 
UKF-NB-3rYM15520nMIII 1.27 ± 0.01 (1.2) 10.8 ± 6.4 (6.2) 122 ± 24 (0.7) 0.62 ± 0.01 (2.1) 1.06 ± 0.24 (0.8) 
UKF-NB-3rYM15520nMIV 0.47 ± 0.03 (0.4) 18.5 ± 8.4 (11) 159 ± 38 (0.9) 0.23 ± 0.04 (0.8) 1.56 ± 0.65 (1.2) 
UKF-NB-3rYM15520nMV 0.99 ± 0.13 (0.9) 8.90 ± 7.39 (5.1) 156 ± 84 (0.9) 0.12 ± 0.04 (0.4) 0.91 ± 0.41 (0.7) 
UKF-NB-3rYM15520nMVI 0.64 ± 0.01 (0.6) 714 ± 456 (408) 132 ± 39 (0.8) 0.64 ± 0.01 (2.1) 1.55 ± 0.72 (1.2) 
UKF-NB-3rYM15520nMVII 1.27 ± 0.04 (1.2) 28.8 ± 10.2 (16) 134 ± 6 (0.8) 0.19 ± 0.01 (0.6) 1.44 ± 0.84 (1.1) 
UKF-NB-3rYM15520nMVIII 0.70 ± 0.01 (0.7) 39.5 ± 15.4 (23) 190 ± 56 (1.1) 0.65 ± 0.01 (2.2) 1.26 ± 0.50 (1.0) 
UKF-NB-3rYM15520nMIX 0.33 ± 0.01 (0.3) 5.63 ± 1.94 (3.2) 178 ± 41 (1.1) 0.18 ± 0.01 (0.6) 1.59 ± 0.74 (1.2) 
UKF-NB-3rYM15520nMX 0.64 ± 0.15 (0.6) 26.0 ± 6.2 (15) 144 ± 44 (0.9) 0.54 ± 0.01 (1.8) 1.21 ± 0.40 (0.9) 
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Figure S1. Representative photos of the project cell lines indicating cell morphology after different periods of cultivation 





















































Figure S3. Representative Western blots indicating cellular levels of survivin in UKF-
NB-3 and YM155-adapted UKF-NB-3 sub-lines. Densitometric analysis was performed
with Image Studio Ver. 5.2 software (LICOR). Survivin levels were normalised to β-










































































relative to β-actin 0.320 0.312 0.341 0.356 0.235 0.358






















































































relative to β-actin 0.38 0.27 0.24 0.48 0.40 0.43















































































































































relative to β-actin 0.62 10.4 2.72 2.65 1.94 1.48








relative to β-actin 0.28 34.0 1.58 1.61 0.67 0.77















































relative to β-actin 69.0 20.9 61.9 53.6 34.6 53.2













































relative to β-actin32.9 21.6 25.0 24.0 22.9 16.5




















































































Figure S5. Representative Western blots indicating cellular levels of ABCB1 and
SLC35F2 in UKF-NB-3 and YM155-adapted UKF-NB-3 sub-lines. Densitometric
analysis was performed with QuantiOne (BioRad). ABCB1 and SLC35F2 levels were































SMART pool siRNA 1 siRNA 2
Figure S6. Western blots indicating cellular levels of survivin levels after transfection
with the Dharmacon SMART pool (consisting of four siRNAs) and two individual
siRNAs (siRNA 1, target sequence: GCAAAGGAAACCAACAAUA; siRNA 2, target
sequence: GGAAAGGAGAUCAACAUUU) in UKF-NB-3 48h and representative



























Figure S6. Original blots, densitometric analysis was performed with QuantiOne
(BioRad). Survivin levels were normalised to β-actin expression and values relative to
control cells are displayed.
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